WO2017092711A1 - 一种人乳头瘤病毒11型l1蛋白的突变体 - Google Patents

一种人乳头瘤病毒11型l1蛋白的突变体 Download PDF

Info

Publication number
WO2017092711A1
WO2017092711A1 PCT/CN2016/108349 CN2016108349W WO2017092711A1 WO 2017092711 A1 WO2017092711 A1 WO 2017092711A1 CN 2016108349 W CN2016108349 W CN 2016108349W WO 2017092711 A1 WO2017092711 A1 WO 2017092711A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
hpv
hpv11
type
amino acid
Prior art date
Application number
PCT/CN2016/108349
Other languages
English (en)
French (fr)
Inventor
李少伟
王大宁
柳欣林
李智海
张军
夏宁邵
Original Assignee
厦门大学
厦门万泰沧海生物技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 厦门大学, 厦门万泰沧海生物技术有限公司 filed Critical 厦门大学
Priority to JP2018548264A priority Critical patent/JP6920694B2/ja
Priority to US15/781,328 priority patent/US10513541B2/en
Priority to BR112018011331-0A priority patent/BR112018011331A2/pt
Priority to KR1020187018923A priority patent/KR20180084139A/ko
Priority to EP16870021.9A priority patent/EP3385274B1/en
Publication of WO2017092711A1 publication Critical patent/WO2017092711A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Definitions

  • the invention relates to the field of molecular virology and immunology.
  • the present invention relates to a mutant HPV11L1 protein (or variant thereof), a coding sequence thereof and a method of preparation, and a virus-like particle comprising the same, the protein (or variant thereof) and the virus-like particle capable of inducing resistance
  • Neutralizing antibodies to at least two types of HPV e.g., HPV11 and HPV6
  • the invention further relates to the use of the above proteins and virus-like particles for the preparation of a pharmaceutical composition or vaccine, which pharmaceutical composition or vaccine is useful for preventing at least two types of HPV infections and diseases caused by said infections For example, cervical cancer and genital warts.
  • HPV Human papillomavirus
  • HPV Human papillomavirus
  • HPV can be divided into high-risk type and low-risk type, among which high-risk HPV infection is confirmed to be the main cause of genital cancer including cervical cancer in women; low-risk type mainly causes condyloma acuminata .
  • the most effective way to prevent and control HPV infection is to vaccinate HPV vaccines, especially those that cause high-risk HPV that can cause cervical cancer.
  • the major capsid protein L1 of HPV has the property of self-assembly into a virus-like particle (VLP).
  • the HPV VLP is a icosahedral stereo-symmetric structure composed of a pentamer of 72 major capsid proteins L1 (Doorbar, J. and P. H. Gallimore. 1987. J Virol, 61(9): 2793-9).
  • the structure of HPV VLPs is highly similar to that of native HPV, retaining most of the neutralizing epitopes of natural viruses and inducing high titers of neutralizing antibodies (Kirnbauer, R., F.Booy, et al. 1992 Proc Natl Acad Sci U S A 89(24): 12180-4).
  • HPV VLPs primarily induce neutralizing antibodies against homologous HPV, producing protective immunity against homologous HPV, while low cross-protection exists only between some highly homologous types (Sara L. Bissett, Giada Mattiuzzo, et al. 2014 Vaccine. 32: 6548-6555). Therefore, the scope of protection of existing HPV vaccines is very limited. Usually, a type of HPV VLP can only be used to prevent this type of HPV infection. In this case, if you want to expand the scope of HPV vaccine protection, you can only add more types of HPV VLPs to the vaccine.
  • HPV vaccines including Merck (It is a four-valent vaccine for HPV16, 18, 6 and 11), GSK's (It is a bivalent vaccine for HPV 16, 18) and Merck (It is a nine-valent vaccine), which is made by mixing multiple types of HPV VLPs.
  • Merck It is a four-valent vaccine for HPV16, 18, 6 and 11
  • GSK's It is a bivalent vaccine for HPV 16, 18
  • Merck It is a nine-valent vaccine
  • HPV virus-like particles capable of inducing protective neutralizing antibodies against multiple types of HPV to more effectively and effectively prevent multiple types of HPV infections and the resulting diseases such as cervical cancer. And genital warts.
  • the present invention is based, at least in part, on the inventors' surprising finding that after replacing a particular segment of the human papillomavirus (HPV) type 11 L1 protein with a corresponding segment of a second type of HPV (eg, HPV6) L1 protein
  • HPV human papillomavirus
  • HPV6 second type of HPV
  • the obtained mutated HPV11L1 protein is capable of inducing the body to produce high titer neutralizing antibodies against HPV11 and a second type of HPV (eg, HPV6), the protective effect of which is comparable to that of the mixed HPV11 VLP and the second type of HPV VLP.
  • the protective effect against HPV11 is comparable to that of HPV11VLP alone
  • the protection effect for the second type of HPV (such as HPV6) is comparable to that of the second type of HPV VLP alone.
  • the invention provides a mutant HPV11L1 protein or variant thereof, wherein the mutated HPV11L1 protein has the following mutations compared to the wild-type HPV11L1 protein:
  • N-terminal truncation of 3-6 amino acids such as 3, 4, 5 or 6 amino acids
  • the variant differs from the mutated HPV11L1 protein by only one or several (eg, 1, 2, 3, 4, 5, 6, 7, 8, or 9) A substitution (preferably conservative substitution), addition or deletion of an amino acid, and retaining the function of the mutated HPV11L1 protein, i.e., capable of inducing neutralizing antibodies against at least two types of HPV (e.g., HPV11 and HPV6).
  • the mutated HPV11L1 protein has a N-terminal truncation of 3, 4, 5 or 6 amino acids compared to the wild-type HPV11L1 protein.
  • the mutated HPV11L1 protein has a N-terminal truncation of 4 amino acids compared to the wild-type HPV11L1 protein.
  • the second type of wild-type HPV is HPV6.
  • the amino acid residue at the corresponding position described in (2) (a) is the amino acid residue at positions 169-178 of the wild-type HPV6L1 protein.
  • the second type of wild-type HPV is HPV6.
  • the amino acid residue at the corresponding position described in (2) (b) is the amino acid residue at positions 345-350 of the wild-type HPV6L1 protein.
  • the second type of wild-type HPV is HPV6.
  • the amino acid residue at the corresponding position described in (2) (c) is the amino acid residue at positions 119-139 of the wild-type HPV6L1 protein.
  • the wild type HPV 11 L1 protein has the amino acid sequence set forth in SEQ ID NO: 1.
  • the wild type HPV6L1 protein has the amino acid sequence set forth in SEQ ID NO:2.
  • sequence of amino acid residues at positions 169-178 of the wild-type HPV6L1 protein is set forth in SEQ ID NO:35.
  • sequence of the amino acid residues at positions 345-350 of the wild-type HPV6L1 protein is set forth in SEQ ID NO:36.
  • sequence of the amino acid residues at positions 119-139 of the wild-type HPV6L1 protein is set forth in SEQ ID NO:37.
  • the mutated HPV11L1 protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 7, and 9.
  • the invention provides an isolated nucleic acid encoding a mutated HPV11L1 protein or variant thereof as described above.
  • the invention provides a vector comprising the isolated nucleic acid.
  • the isolated nucleic acid of the invention has a nucleotide sequence selected from the group consisting of SEQ ID NO: 13, 14 and 16.
  • Vectors useful for insertion of a polynucleotide of interest include, but are not limited to, cloning vectors and expression vectors.
  • the vector is, for example, a plasmid, a cosmid, a phage, and the like.
  • the invention also relates to a host cell comprising the isolated nucleic acid or vector described above.
  • host cells include, but are not limited to, prokaryotic cells such as E. coli cells, and eukaryotic cells such as yeast cells, insect cells, plant cells, and animal cells (eg, mammalian cells, such as mouse cells, human cells, etc.).
  • the host cell of the invention may also be a cell line, such as a 293T cell.
  • the present invention relates to an HPV virus-like particle, wherein the virus-like particle comprises or is composed or formed of the mutated HPV11L1 protein of the present invention or a variant thereof.
  • the HPV virus-like particle of the invention comprises a mutated HPV11L1 protein that is N-terminally truncated by 3-6 amino acids compared to the wild-type HPV11L1 protein, eg, 3, 4, 5 Or 6 amino acids, and the amino acid residues at positions 170-179 of the wild type HPV11L1 protein were replaced with amino acid residues at positions 169-178 of the wild type HPV6L1 protein.
  • the HPV virus-like particle of the invention comprises a mutated HPV11L1 protein that is N-terminally truncated by 3-6 amino acids compared to the wild-type HPV11L1 protein, eg, 3, 4, 5 Or 6 amino acids, and the amino acid residues at positions 346-351 of the wild-type HPV11L1 protein are replaced with amino acid residues at positions 345-350 of the wild-type HPV6L1 protein.
  • the HPV virus-like particle of the invention comprises a mutated HPV11L1 protein that is N-terminally truncated by 3-6 amino acids compared to the wild-type HPV11L1 protein, eg, 3, 4, 5 Or 6 amino acids, and the amino acid residues at positions 119-140 of the wild-type HPV11L1 protein were replaced with amino acid residues at positions 119-139 of the wild-type HPV6L1 protein.
  • the HPV virus-like particle of the invention comprises a mutated HPV11L1 protein having the sequence set forth in SEQ ID NO: 6, 7, or 9.
  • the invention also relates to a composition
  • a composition comprising the above-described mutated HPV11L1 protein or variant thereof, or the above isolated nucleic acid or vector or host cell or HPV virus-like particle.
  • the composition comprises a mutated HPV11L1 protein of the invention or a variant thereof.
  • the composition comprises HPV virus-like particles of the invention.
  • the invention also relates to a pharmaceutical composition or vaccine comprising an HPV virus-like particle of the invention, optionally further comprising a pharmaceutically acceptable carrier and/or excipient.
  • the pharmaceutical composition or vaccine of the present invention can be used for preventing HPV infection or diseases caused by HPV infection such as cervical cancer and condyloma acuminatum.
  • the HPV virus-like particle is present in an amount effective to prevent HPV infection or a disease caused by HPV infection.
  • the HPV infection is one or more types of HPV infection (eg, HPV 11 infection and/or HPV 6 infection).
  • the disease caused by HPV infection is selected from white cervical cancer and condyloma acuminatum.
  • compositions or vaccines of the invention may be administered by methods well known in the art such as, but not limited to, administration by oral or injection.
  • a particularly preferred mode of administration is injection.
  • the pharmaceutical compositions or vaccines of the invention are administered in unit dosage form.
  • the amount of HPV virus-like particles contained per unit dose is from 5 ⁇ g to 80 ⁇ g, preferably from 20 ⁇ g to 40 ⁇ g.
  • the invention in another aspect, relates to a method of producing a mutated HPV11L1 protein or variant thereof as described above, comprising expressing said mutated HPV11L1 protein or variant thereof in a host cell, and then from said host The mutated HPV11L1 protein or variant thereof is recovered from the culture of the cells.
  • the host cell is E. coli.
  • the method comprises the steps of: expressing the mutated HPV11L1 protein or variant thereof in E. coli, and then purifying the mutated HPV11L1 protein from the lysed supernatant of the E. coli Or its variants.
  • the mutated HPV11L1 protein is recovered from the lysed supernatant of the E. coli by chromatography (eg, cation exchange chromatography, hydroxyapatite chromatography, and/or hydrophobic interaction chromatography). Or its variants.
  • the invention in another aspect, relates to a method of preparing a vaccine comprising mixing an HPV virus-like particle of the invention with a pharmaceutically acceptable carrier and/or excipient.
  • the present invention relates to a method of preventing HPV infection or a disease caused by HPV infection comprising administering a prophylactically effective amount of an HPV virus-like particle or pharmaceutical composition or vaccine according to the present invention to a subject .
  • the HPV infection is one or more types of HPV infections (eg, HPV11) Infection and / or HPV6 infection).
  • the disease caused by HPV infection includes, but is not limited to, cervical cancer and condyloma acuminata.
  • the subject is a mammal, such as a human.
  • the invention relates to the use of a mutant HPV11L1 protein or variant thereof or HPV virus-like particle according to the invention for the preparation of a pharmaceutical composition or vaccine for the prevention of HPV infection or by HPV
  • HPV infection is one or more types of HPV infection (eg, HPV 11 infection and/or HPV 6 infection).
  • the disease caused by HPV infection includes, but is not limited to, cervical cancer and condyloma acuminata.
  • type 2 wild-type HPV means another type of wild-type HPV different from HPV11.
  • the second type of wild-type HPV is preferably wild type HPV6.
  • corresponding position means an equivalent position in a sequence to be compared when the sequences are optimally aligned, i.e., when the sequences are aligned to obtain the highest percentage identity.
  • wild-type HPV11L1 protein refers to the major capsid protein L1 naturally present in human papillomavirus type 11 (HPV11).
  • HPV11 human papillomavirus type 11
  • the sequence of the wild-type HPV11L1 protein is well known in the art and can be found in various public databases (e.g., HPV11L1 protein encoded by NCBI database accession numbers M14119.1, AF335603.1, AF335602.1, etc.).
  • amino acid sequence of the wild-type HPV11L1 protein when referring to the amino acid sequence of the wild-type HPV11L1 protein, the description is made with reference to the sequence shown in SEQ ID NO: 1.
  • amino acid residues 170-179 of the wild type HPV11L1 protein means the amino acid residues 170 to 179 of the polypeptide represented by SEQ ID NO: 1.
  • wild-type HPV11 may include a plurality of isolates, and there may be a difference between the amino acid sequences of the L1 proteins of the various isolates.
  • wild-type HPV11L1 protein includes not only the protein represented by SEQ ID NO: 1, but also the L1 protein of various HPV11 isolates (for example, NCBI database accession numbers M14119.1, AF335603.1, AF335602). .1 and so on encoded HPV11L1 protein).
  • sequence fragment of the wild type HPV11L1 protein includes not only the sequence fragment of SEQ ID NO: 1, but also the corresponding sequence fragment of the L1 protein of various HPV11 isolates.
  • amino acid residues 170-179 of the wild-type HPV11L1 protein includes amino acid residues 170-179 of SEQ ID NO: 1, and corresponding fragments of the L1 proteins of various HPV11 isolates.
  • wild-type HPV6L1 protein refers to the major capsid protein L1 naturally present in human papillomavirus type 6 (HPV6).
  • HPV6L1 protein encoded by NCBI database accession number AF067042.1, AF092932.1, L41216.1, X00203.1, etc.).
  • amino acid residue at positions 169 to 178 of the wild-type HPV6L1 protein means the amino acid residues 169 to 178 of the polypeptide represented by SEQ ID NO: 2.
  • wild-type HPV6 may include a plurality of isolates, and there may be a difference between the amino acid sequences of the L1 proteins of the various isolates.
  • wild-type HPV6L1 protein includes not only the protein represented by SEQ ID NO: 2 but also the L1 protein of various HPV6 isolates (for example, NCBI database accession number AF067042.1, AF092932.1). , HPV6L1 protein encoded by L41216.1, X00203.1, etc.).
  • sequence fragment of the wild type HPV6L1 protein includes not only the sequence fragment of SEQ ID NO: 2 but also the corresponding sequence fragment in the L1 protein of various HPV6 isolates.
  • amino acid residues 169-178 of the wild-type HPV6L1 protein includes amino acid residues 169-178 of SEQ ID NO: 2, and corresponding fragments of the L1 proteins of various HPV6 isolates.
  • corresponding sequence fragment or “corresponding fragment” means that when the sequences are optimally aligned, ie when the sequences are aligned to obtain the highest percentage identity, the sequences to be compared are in the equivalent position. Fragment of.
  • the expression "N-terminally truncated X amino acids” means using a start codon (for starting protein)
  • the translated methionine residue replaces the amino acid residues 1-N of the N-terminus of the protein.
  • the HPV11L1 protein having a N-terminally truncated 4 amino acid refers to a protein obtained by replacing the amino acid residues 1-4 of the N-terminus of the wild-type HPV11L1 protein with a methionine residue encoded by the initiation codon.
  • the term "variant" refers to a protein having an amino acid sequence having an amino acid sequence as compared with the amino acid sequence of the mutated HPV11L1 protein of the present invention (such as the protein shown in SEQ ID NO: 6, 7, or 9). Or a few (eg, 1, 2, 3, 4, 5, 6, 7, 8, or 9) amino acid substitutions (preferably conservative substitutions), additions or deletions, or having at least 90 %, 95%, 96%, 97%, 98%, or 99% identity, and it retains the function of the mutated HPV11L1 protein.
  • the term "function of a mutated HPV11L1 protein” means that a neutralizing antibody capable of inducing production of at least two types of HPV (for example, HPV11 and HPV6) can be induced.
  • the term “identity” is a measure of the similarity to a nucleotide sequence or amino acid sequence. The sequences are usually arranged to get the maximum match. "Identity” itself has a meaning that is well known in the art and can be calculated using published algorithms such as BLAST.
  • the term "identity" is used to mean the matching of sequences between two polypeptides or between two nucleic acids.
  • a position in the two sequences being compared is occupied by the same base or amino acid monomer subunit (for example, a position in each of the two DNA molecules is occupied by adenine, or two
  • Each position in each of the polypeptides is occupied by lysine, and then each molecule is identical at that position.
  • the "percent identity" between the two sequences is a function of the number of matching positions shared by the two sequences divided by the number of positions to be compared x 100. For example, if 6 of the 10 positions of the two sequences match, then the two sequences have 60% identity.
  • the DNA sequences CTGACT and CAGGTT share 50% identity (3 out of a total of 6 positions match).
  • the comparison is made when the two sequences are aligned to produce maximum identity.
  • Such alignment can be achieved by using, for example, the method of Needleman et al. (1970) J. Mol. Biol. 48: 443-453, which is conveniently performed by a computer program such as the Align program (DNAstar, Inc.). It is also possible to use the algorithm of E. Meyers and W. Miller (Comput. Appl Biosci., 4: 11-17 (1988)) integrated into the ALIGN program (version 2.0), using the PAM 120 weight residue table.
  • the gap length penalty of 12 and the gap penalty of 4 were used to determine the percent identity between the two amino acid sequences.
  • the Needleman and Wunsch (J MoI Biol. 48: 444-453 (1970)) algorithms in the GAP program integrated into the GCG software package can be used, using the Blossum 62 matrix or The PAM250 matrix and the gap weight of 16, 14, 12, 10, 8, 6 or 4 and the length weight of 1, 2, 3, 4, 5 or 6 to determine the percent identity between two amino acid sequences .
  • conservative substitution means an amino acid substitution that does not adversely affect or alter the essential properties of a protein/polypeptide comprising an amino acid sequence.
  • conservative substitutions can be introduced by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis.
  • Conservative amino acid substitutions include substitutions of amino acid residues with similar side chains in place of amino acid residues, for example, physically or functionally similar to corresponding amino acid residues (eg, having similar size, shape, charge, chemical properties, including Substitution of residues by formation of a covalent bond or a hydrogen bond, etc.).
  • a family of amino acid residues having similar side chains has been defined in the art.
  • These families include basic side chains (eg, lysine, arginine, and histidine), acidic side chains (eg, aspartic acid, glutamic acid), uncharged polar side chains (eg, glycine) , asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), non-polar side chains (eg alanine, valine, leucine, isoluminescence) Acid, valine, phenylalanine, methionine), beta branch side chains (eg, threonine, valine, isoleucine) and aromatic side chains (eg, tyrosine, Amino acids of phenylalanine, tryptophan, histidine).
  • basic side chains eg, lysine, arginine, and histidine
  • acidic side chains eg, aspartic acid, glutamic acid
  • uncharged polar side chains eg, glycine
  • conservative substitutions generally refer to the replacement of the corresponding amino acid residue with another amino acid residue from the same side chain family.
  • Methods for identifying conservative substitutions of amino acids are well known in the art (see, for example, Brummell et al, Biochem. 32: 1180-1187 (1993); Kobayashi et al., Protein Eng. 12 (10): 879-884 (1999). And Burks et al. Proc. Natl Acad. Set USA 94: 412-417 (1997), which is incorporated herein by reference.
  • E. coli expression system refers to an expression system consisting of E. coli (strain) and a vector, wherein E. coli (strain) is derived from commercially available strains such as, but not limited to, ER2566, BL21 ( DE3), B834 (DE3), BLR (DE3).
  • the term "vector” refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted.
  • a vector is referred to as an expression vector when the vector enables expression of a protein encoded by the inserted polynucleotide.
  • the vector can be introduced into the host cell by transformation, transduction or transfection, and the genetic material element carried thereby can be expressed in the host cell.
  • Vectors are well known to those skilled in the art and include, but are not limited to, plasmids; phage; cosmid and the like.
  • the term "pharmaceutically acceptable carrier and/or excipient” means a carrier and/or excipient which is pharmacologically and/or physiologically compatible with the subject and the active ingredient, which is in the art It is well known (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995) and includes, but is not limited to, pH adjusting agents, surfactants, adjuvants, ionic strength enhancers.
  • pH adjusting agents include, but are not limited to, phosphate buffers; surfactants include, but are not limited to, cationic, anionic or nonionic surfactants such as Tween-80; adjuvants These include, but are not limited to, aluminum adjuvants (eg, aluminum hydroxide), Freund's adjuvant (eg, complete Freund's adjuvant); ionic strength enhancers include, but are not limited to, sodium chloride.
  • aluminum adjuvants eg, aluminum hydroxide
  • Freund's adjuvant eg, complete Freund's adjuvant
  • ionic strength enhancers include, but are not limited to, sodium chloride.
  • an effective amount means an amount effective to achieve the intended purpose.
  • an effective amount to prevent disease e.g., HPV infection
  • an effective amount that is effective to prevent, prevent, or delay the onset of a disease e.g., HPV infection. Determination of such effective amounts is well within the abilities of those skilled in the art.
  • chromatography includes, but is not limited to, ion exchange chromatography (eg cation exchange chromatography), hydrophobic interaction chromatography, adsorption chromatography (eg hydroxyapatite chromatography), gel filtration (gel discharge) Resistance) chromatography, affinity chromatography.
  • the term "lytic supernatant” refers to a solution produced by disrupting a host cell, such as E. coli, in a lysate, and then insolubles in the lysate containing the disrupted host cell. Remove.
  • a host cell such as E. coli
  • phosphate buffer such as HEPES buffer
  • MOPS buffer such as Tris buffer
  • disruption of host cells can be accomplished by a variety of methods well known to those skilled in the art including, but not limited to, homogenizer disruption, homogenizer disruption, sonication, milling, high pressure extrusion, lysozyme treatment, and the like.
  • Methods of removing insolubles from the lysate are also well known to those skilled in the art and include, but are not limited to, filtration and centrifugation.
  • the present invention provides a mutant HPV11L1 protein and HPV virus-like particles formed therefrom.
  • the HPV virus-like particles of the invention are capable of providing significant cross-protection between HPV 11 and other types of HPV (e.g., HPV6).
  • the HPV virus-like particles of the present invention are capable of inducing the body to produce high titer neutralizing antibodies against at least two types of HPV (eg, HPV11 and HPV6), and the effect thereof and multiple types
  • a mixture of other HPV VLPs eg, a mixture of HPV 11 VLP and HPV 6 VLP
  • HPV 11 VLP a mixture of HPV 11 VLP and HPV 6 VLP
  • the HPV virus-like particles of the present invention can be used to simultaneously prevent infection of at least two types of HPV (e.g., HPV11 and HPV6) and diseases associated therewith, with significant advantageous technical effects.
  • HPV e.g., HPV11 and HPV6
  • This has a particularly significant advantage in expanding the scope of protection of HPV vaccines and reducing the cost of production of HPV vaccines.
  • Figure 1 shows the results of SDS polyacrylamide gel electrophoresis of the purified mutant protein of Example 1.
  • Lane M protein molecular weight marker
  • Lane 1 HPV11N4 (HPV11L1 protein with N-terminally truncated 4 amino acids)
  • Lane 2 H11N4-6T1
  • Lane 3 H11N4-6T2
  • Lane 4 H11N4-6T3
  • Lane 5 H11N4 -6T4
  • Lane 6 H11N4-6T5.
  • the results showed that the purity of the proteins H11N4-6T1, H11N4-6T2, H11N4-6T3, H11N4-6T4 and H11N4-6T5 was over 95% after chromatographic purification.
  • FIGS. 2A-2F show the results of molecular sieve chromatography analysis of samples containing the proteins HPV11N4, H11N4-6T1, H11N4-6T2, H11N4-6T3, H11N4-6T4, and H11N4-6T5.
  • Figure 2A HPV11N4;
  • Figure 2B H11N4-6T1;
  • Figure 2C H11N4-6T2;
  • Figure 2D H11N4-6T3;
  • Figure 2E H11N4-6T4;
  • Figure 2F H11N4-6T5.
  • the results showed that the first peaks of the samples containing H11N4-6T1, H11N4-6T2, H11N4-6T3, H11N4-6T4 and H11N4-6T5 were around 12 min, which was comparable to HPV11N4 VLP. This indicates that the above mutant protein assembly can be assembled into a VLP.
  • FIGS 3A-3F show the results of sedimentation rate analysis of HPV11N4VLP, H11N4-6T1VLP, H11N4-6T2VLP, H11N4-6T3VLP, H11N4-6T4VLP, and H11N4-6T5VLP.
  • Figure 3A HPV11N4VLP
  • Figure 3B H11N4-6T1VLP
  • Figure 3C H11N4-6T2VLP
  • Figure 3D H11N4-6T3VLP
  • Figure 3E H11N4-6T4VLP
  • Figure 3F H11N4-6T5VLP.
  • Figure 4A HPV11N4VLP
  • Figure 4B H11N4-6T1VLP
  • Figure 4C H11N4-6T2VLP
  • Figure 4D H11N4-6T3VLP
  • Figure 4E H11N4-6T4VLP
  • Figure 4F H11N4-6T5VLP.
  • the results show that H11N4-6T1, H11N4-6T2, H11N4-6T3, H11N4-6T4 and H11N4-6T5 are similar to HPV11N4, and can be assembled into VLPs with a radius of about 25 nm.
  • FIGS 5A-5F show the results of thermal stability evaluation of VLPs formed by HPV11N4, H11N4-6T1, H11N4-6T2, H11N4-6T3, H11N4-6T4, and H11N4-6T5.
  • Figure 5A HPV11N4VLP
  • Figure 5B H11N4-6T1VLP
  • Figure 5C H11N4-6T2VLP
  • Figure 5D H11N4-6T3VLP
  • Figure 5E H11N4-6T4VLP
  • Figure 5F H11N4-6T5VLP.
  • the results show that the VLP formed by each protein has extremely high thermal stability.
  • FIG. 6A-6D show the results obtained by observing H11N4-6T3VLP and H11N4-6T5VLP using a cryo-electron microscope and analyzing their structures; wherein, FIG. 6A and FIG. 6C respectively show the results of cryo-electron microscopy of H11N4-6T3VLP and H11N4-6T5VLP; 6B and FIG. 6D respectively show the three-dimensional structures of H11N4-6T3VLP and H11N4-6T5VLP analyzed by cryo-electron microscopy, and their resolutions are respectively with
  • FIG. 7 shows the results of evaluation of immunoprotection of experimental groups H11N4-6T1, H11N4-6T2, H11N4-6T3, H11N4-6T4 and H11N4-6T5 with the control HPV11N4 VLP, HPV6N5 VLP and mixed HPV11/HPV6 VLP in mice.
  • H11N4-6T2VLP also induced high titers of neutralizing antibodies against HPV11 and HPV6 in mice, but its ability to induce anti-HPV6 neutralizing antibodies was weaker than H11N4-6T3 VLP and H11N4-6T5 VLP.
  • Figures 8A-8C show the results of evaluation of neutralizing antibody titers in mouse serum after immunization of mice with H11N4-6T3VLP and H11N4-6T5VLP.
  • Figure 8A Aluminum adjuvant group 1 (immunization dose 10 ⁇ g, using aluminum adjuvant);
  • Figure 8B aluminum adjuvant group 2 (immunization dose 1 ⁇ g, using aluminum adjuvant);
  • Figure 8C aluminum adjuvant group 3 (immunization) The dose was 0.1 ⁇ g using an aluminum adjuvant).
  • H11N4-6T3VLP and H11N4-6T5VLP could induce high titers of neutralizing antibodies against HPV11 in mice, and the protective effect was comparable to that of the same dose of HPV11N4VLP, mixed HPV11/HPV6VLP, and significantly better than the same A dose of HPV6N5VLP alone; and it can induce high titers of neutralizing antibodies against HPV6 in mice, with a protective effect comparable to that of the same dose of HPV6N5 VLP alone, mixed HPV11/HPV6 VLP, and significantly better than the same dose alone HPV11N4VLP.
  • Figure 9 shows the results of evaluation of neutralizing antibody titers in cynomolgus monkey serum after immunization of cynomolgus monkeys with H11N4-6T3VLP and H11N4-6T5VLP.
  • the results showed that H11N4-6T3VLP and H11N4-6T5VLP each induced crab eating Monkeys produced high titers of neutralizing antibodies against HPV11 and HPV6 with comparable protective effects to mixed HPV11/HPV6 VLPs. This indicates that each of H11N4-6T3VLP and H11N4-6T5VLP has good cross-immunogenicity and cross-protection against HPV11 and HPV6.
  • Sequence 7 (SEQ ID NO: 7):
  • Sequence 8 (SEQ ID NO: 8):
  • Sequence 9 (SEQ ID NO: 9):
  • a multi-point mutation PCR reaction was used to construct an expression vector encoding a HPV11L1 protein (H11N4-6T1) containing a mutation derived from a specific segment of the HPV6L1 protein, wherein the initial template used was pT0-T7-HPV11N4C plasmid (which encodes N The 4 amino acid HPV11L1 protein was truncated at the end; in Table 2, it is abbreviated as 11L1N4).
  • the template and primers used for each PCR reaction are shown in Table 2, and the amplification conditions of the PCR reaction were set to: denaturation at 94 ° C for 10 minutes; 25 cycles (denaturation at 94 ° C for 50 seconds, annealing at a specified temperature for a certain time, extension at 72 ° C) 7 minutes and 30 seconds); last 7 minutes at 72 ° C.
  • the specific sequences of the PCR primers used are listed in Table 3.
  • the mutein H11N4-6T1 differs from HPV11N4 in that amino acid residues at positions 49-63 of the wild-type HPV11L1 protein are replaced with amino acid residues at positions 49-63 of the wild-type HPV6L1 protein.
  • the initial templates used included the pT0-T7-HPV11N4C plasmid and the pT0-T7-HPV6N5C plasmid (which encodes the HPV6L1 protein with a N-terminal truncation of 5 amino acids; abbreviated as 6L1N5 in Table 2).
  • the templates and primers used for the respective PCR reactions are shown in Table 2, and the amplification conditions for the PCR reaction for amplifying the short fragments were set to: denaturation at 94 ° C for 10 minutes; 25 cycles (denaturation at 94 ° C for 50 seconds, specified temperature) Annealing for a certain period of time, extending at 72 ° C for 1 minute); finally extending at 72 ° C for 10 minutes.
  • the amplification conditions for the PCR reaction for amplifying the long fragment were set to: denaturation at 94 ° C for 10 minutes; 25 cycles (denaturation at 94 ° C for 50 seconds, annealing at a specified temperature for a certain time, extension at 72 ° C for 7 minutes and 30 seconds); °C extended for 10 minutes.
  • the specific sequences of the PCR primers used are listed in Table 3.
  • the amplified product was subjected to electrophoresis, and then the target fragment was recovered using a DNA recovery kit and its concentration was determined.
  • the amplified short and long fragments were mixed at a molar ratio of 2:1 (total volume 3 ⁇ L), followed by the addition of 3 ⁇ L of 2X Gibson Assembly Premix (2X Gibson Assembly Master Mix, purchased from NEB, containing T5exonuclease, Phusion DNA polymerase , Taq DNA ligase), and reacted at 50 ° C for 1 hour.
  • 2X Gibson Assembly Master Mix purchased from NEB, containing T5exonuclease, Phusion DNA polymerase , Taq DNA ligase
  • nucleotide sequence of the target fragment inserted into the plasmid was sequenced using a T7 primer.
  • the sequencing results showed that the nucleotide sequences of the target fragments inserted in each of the constructed plasmids (expression vectors) were SEQ ID NOs: 13, 14, 15, and 16, respectively, and the encoded amino acid sequences thereof.
  • SEQ ID NOS: 6, 7, 8, and 9 the corresponding proteins are designated as H11N4-6T2, H11N4-6T3, H11N4-6T4, and H11N4-6T5, respectively).
  • the mutein H11N4-6T2 differs from HPV11N4 in that amino acid residues at positions 119-140 of the wild-type HPV11L1 protein are replaced with amino acid residues at positions 119-139 of the wild-type HPV6L1 protein.
  • the mutein H11N4-6T3 differs from HPV11N4 in that amino acid residues at positions 170-179 of the wild-type HPV11L1 protein are replaced with amino acid residues at positions 169-178 of the wild-type HPV6L1 protein.
  • the mutein H11N4-6T4 differs from HPV11N4 in that amino acid residues at positions 257-288 of the wild-type HPV11L1 protein are replaced with amino acid residues at positions 256-287 of the wild-type HPV6L1 protein.
  • the mutein H11N4-6T5 differs from HPV11N4 in that amino acid residues at positions 346-351 of the wild-type HPV11L1 protein are replaced with amino acid residues at positions 345-350 of the wild-type HPV6L1 protein.
  • the recombinant plasmids pT0-T7-H11N4-6T1, pT0-T7-H11N4-6T2, pT0-T7-H11N4-6T3, pT0-T7-H11N4-6T4, pT0-T7-H11N4-6T5 were taken out from the -70 °C refrigerator.
  • the E. coli bacteria were inoculated into 100 ml of LB liquid medium containing kanamycin, and cultured at 200 rpm, 37 ° C for about 8 hours; then transferred to 500 ml of LB medium containing kanamycin. Into 1 ml of bacterial solution), and continue to culture.
  • the culture temperature was lowered to 25 ° C, and 500 ⁇ L of IPTG was added to each flask, and the culture was continued for 8 hours. After the completion of the culture, the cells were collected by centrifugation. The cells expressing the H11N4-6T1, H11N4-6T2, H11N4-6T3, H11N4-6T4 and H11N4-6T5 proteins were obtained.
  • the above-obtained cells were resuspended in a ratio of 1 g of the bacterium to 10 mL of a lysate (20 mM Tris buffer, pH 7.2, 300 mM NaCl).
  • the cells were disrupted by a sonicator for 30 min.
  • the lysate containing the disrupted cells was centrifuged at 13500 rpm (30000 g) for 15 min to remove the supernatant (i.e., the bacterial cell disrupted supernatant).
  • AKTA explorer 100 preparative liquid chromatography system manufactured by GE Healthcare (formerly Amershan Pharmacia).
  • Chromatographic media SP Sepharose 4 Fast Flow (GE Healthcare), CHT-II (available from Bio-RAD), and Butyl Sepharose 4 Fast Flow (GE Healthcare).
  • Buffer 20 mM phosphate buffer, pH 8.0, 20 mM DTT; and, 20 mM phosphate buffer, pH 8.0, 20 mM DTT, 2 M NaCl.
  • the eluted fraction obtained in the step (3) was 150 ⁇ L, added to 30 ⁇ L of 6X Loading Buffer, mixed, and incubated in a water bath at 80 ° C for 10 min. 10 ⁇ l of the sample was then electrophoresed in a 10% SDS-polyacrylamide gel at 120 V for 120 min; then the electrophoresis band was visualized by Coomassie blue staining. The results of electrophoresis are shown in Figure 1. The results showed that the purity of H11N4-6T1, H11N4-6T2, H11N4-6T3, H11N4-6T4 and H11N4-6T5 proteins was greater than 95% after the above purification steps.
  • HPV11N4 protein was prepared and purified by a similar method using Escherichia coli and pT0-T7-HPV11N4C plasmid; and HPV6N5 protein was prepared and purified using Escherichia coli and pT0-T7-HPV6N5C plasmid.
  • Example 2 Assembly and particle morphology detection of HPV virus-like particles
  • HPV11N4 and HPV6N5 proteins were assembled into HPV11N4 VLP and HPV6N5 VLP, respectively, by a similar method.
  • the dialyzed samples were analyzed by molecular sieve chromatography using an Agilent 1120 Compact LC system, wherein the analytical column used was TSK Gel PW5000xl 7.8 x 300 mm.
  • the results of the analysis are shown in Figures 2A-2F.
  • the results showed that the first peaks of the proteins containing the proteins H11N4-6T1, H11N4-6T2, H11N4-6T3, H11N4-6T4 and H11N4-6T5 were around 12 min, which was comparable to HPV11N4 VLP. This indicates that the proteins prepared as above can be assembled into VLPs.
  • the instrument used for sedimentation rate analysis was a Beckman XL-A analytical ultracentrifuge equipped with an optical inspection system and An-50Ti and An-60Ti rotors.
  • the sedimentation coefficients of HPV11N4VLP, H11N4-6T1VLP, H11N4-6T2VLP, H11N4-6T3VLP, H11N4-6T4VLP and H11N4-6T5VLP were analyzed by sedimentation rate method. The results are shown in Figures 3A-3F.
  • the thermal stability of VLPs formed by HPV11N4, H11N4-6T1, H11N4-6T2, H11N4-6T3, H11N4-6T4 and H11N4-6T5 was evaluated using a differential temperature calorimeter VP Capillary DSC purchased from GE (formerly MicroCal).
  • the storage buffer of the protein was used as a control, and each protein was scanned at a temperature elevation rate of 1.5 ° C / min in the interval of 10 ° C - 90 ° C.
  • the test results are shown in Figures 5A-5F. The results show that the VLP formed by each protein has extremely high thermal stability.
  • Example 4 Reconstruction of three-dimensional structure of H11N4-6T3VLP and H11N4-6T5VLP
  • H11N4-6T3VLP and H11N4-6T5VLP Particles over 50 nm in diameter are used for computer overlap and structural reconstruction to obtain the three-dimensional structure of H11N4-6T3VLP and H11N4-6T5VLP.
  • the obtained three-dimensional structure is shown in Figures 6B and 6D (resolution is with ).
  • all subunits in the H11N4-6T3 VLP and H11N4-6T5 VLP structures are pentamers, without the presence of hexamers.
  • the outermost diameter of the VLP is about 60 nm.
  • This is in contrast to the previously reported natural HPV virions and the three-dimensional structure of HPV VLPs prepared by eukaryotic expression systems (eg, poxvirus expression systems) (Baker TS, Newcomb WW, Olson NH. et al. Biophys J. (1991), 60(6): 1445-1456; Hagensee ME, Olson NH, Baker TS, et al. J Virol. (1994), 68(7): 4503-4505; Buck CB, Cheng N, Thompson CD. et al. Virol. (2008), 82(11): 5190-7) is similar.
  • mice were used to evaluate the immunoprotective properties of VLPs formed by H11N4-6T1, H11N4-6T2, H11N4-6T3, H11N4-6T4 and H11N4-6T5.
  • the animals used for immunization were 5-6 week old BalB/c normal mice (purchased from Shanghai Sleek Experimental Animal Co., Ltd.).
  • Mice were divided into 8 groups according to different immunogens, and each group contained 4 mice.
  • the immunization procedure was: primary immunization at 0 weeks; booster immunizations at 2 and 4 weeks.
  • the mode of immunization was subcutaneous injection, and the immunogen and dose used were as shown in Table 4.
  • H11N4-6T2VLP also induced high titers of neutralizing antibodies against HPV11 and HPV6 in mice, but its ability to induce anti-HPV6 neutralizing antibodies was weaker than H11N4-6T3 VLP and H11N4-6T5 VLP.
  • Example 6 Evaluation of neutralizing antibody titers in mouse serum after immunization with VLP
  • the immunization schedule is shown in Table 5.
  • Table 5 Divided all mice (6-week old BalB/c female mice) into Three groups: aluminum adjuvant group 1 (immunization dose 10 ⁇ g, using aluminum adjuvant), aluminum adjuvant group 2 (immunization dose 1 ⁇ g, using aluminum adjuvant), and aluminum adjuvant group 3 (immunization dose 0.1 ⁇ g) , using aluminum adjuvant).
  • control subgroups 1-3 used separate HPV11N4 VLPs, HPV6N5 VLPs alone, and mixed HPV11/HPV6 VLPs (ie, a mixture of HPV11N4 VLPs and HPV6N5 VLPs, each of which was designated for immunization). Immunization was performed by dose administration, and subgroups 1-2 were immunized with H11N4-6T3 VLP and H11N4-6T5 VLP, respectively.
  • mice/subgroups were immunized by intraperitoneal injection, and the immunization doses were 10 ⁇ g, 1 ⁇ g, and 0.1 ⁇ g, respectively, and the injection volume was 1 ml. All mice were immunized initially at week 0 and then boosted once each at weeks 2 and 4. The mice were subjected to eyelid blood sampling at week 8, and the titers of anti-HPV6 and HPV11 antibodies in the serum were analyzed. The results of the analysis are shown in Figures 8A-8C.
  • H11N4-6T3VLP and H11N4-6T5VLP could induce high titers of neutralizing antibodies against HPV11 in mice, and the protective effect was comparable to that of the same dose of HPV11N4VLP, mixed HPV11/HPV6VLP, and significantly better than the same A dose of HPV6N5VLP alone; and it can induce a high titer of neutralizing antibodies against HPV6 in mice, which has the same protective effect as the same dose of HPV6N5VLP, mixed HPV11/HPV6VLP, and is significantly better than the same dose alone.
  • HPV11N4VLP This indicates that each of H11N4-6T3VLP and H11N4-6T5VLP has good cross-immunogenicity and cross-protection against HPV11 and HPV6.
  • mice 6-week-old BalB/c female mice (8 rats) were immunized with aluminum adjuvant and single intraperitoneal injection.
  • the experimental group used H11N4-6T3VLP or H11N4-6T5VLP (immunization doses were 0.300 ⁇ g, 0.100 ⁇ g, 0.033).
  • the control group uses HPV6N5VLP alone or HPV11N4VLP alone (immunization dose is 0.300 ⁇ g, 0.100 ⁇ g, 0.033 ⁇ g or 0.011 ⁇ g), or mixed HPV11/HPV6 VLP (ie, a mixture of HPV6N5 VLP and HPV11N4 VLP, each of which The immunization dose of the VLPs was 0.300 ⁇ g, 0.100 ⁇ g, 0.033 ⁇ g, 0.011 ⁇ g or 0.004 ⁇ g each; the immunological volume was 1 mL. In addition, a dilution for the diluted vaccine was also used as a blank control.
  • mice Eight mice were immunized in each group, and serum was collected for the fifth week after immunization. Subsequently, the neutralizing antibody titer in the serum was measured by a neutralization test, and each was calculated according to the Reed-Muench method (Reed LJ MH. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938; 27: 493-7). induce seroconversion samples (i.e., an antibody induced in mice) the ED 50. The experimental results are shown in Tables 6.1-6.5.
  • H11N4-6T3VLP and H11N4-6T5VLP induced ED 50 of anti-HPV6 antibody in mice comparable to HPV6N5VLP and mixed HPV11/HPV6VLP alone, and was significantly better than HPV11N4VLP alone; and, H11N4-6T3VLP and H11N4-6T5VLP induction mice ED 50 anti-HPV11 antibodies alone HPV11N4VLP and mixed HPV11 / HPV6VLP considerable, and significantly superior to separate HPV6N5VLP. This further indicates that H11N4-6T3VLP and H11N4-6T5VLP have good cross-immunogenicity and cross-protection against HPV6 and HPV11.
  • Example 8 Evaluation of immunoprotection of H11N4-6T3 VLP and H11N4-6T5 VLP in cynomolgus monkeys
  • cynomolgus monkeys with similar body weight were randomly divided into 3 groups (6 monkeys in each group). Among them, the first group of monkeys were inoculated with 5 ⁇ g of H11N4-6T3VLP; the second group of monkeys were inoculated with 5 ⁇ g of H11N4-6T5VLP; the third group of monkeys were inoculated. 10 ⁇ g of mixed HPV11/HPV6 VLP (5 ⁇ g HPV6N5 VLP + 5 ⁇ g HPV 11 N4 VLP). The adjuvants used were all aluminum adjuvants, injected in a volume of 1 ml, and immunized by intramuscular injection. The immunization schedule is shown in Table 7.
  • H11N4-6T3VLP and H11N4-6T5VLP each have good immunogenicity in cynomolgus monkeys and can induce cross-protection against HPV6 and HPV11, which protects against HPV11 and HPV6 and mixed HPV11/HPV6VLP quite. Therefore, H11N4-6T3VLP and H11N4-6T5VLP can be used to prevent infection of HPV6 and HPV11.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

一种突变的HPV11 L1蛋白(或其变体)，其编码序列和制备方法，以及包含其的病毒样颗粒，所述蛋白(或其变体)和病毒样颗粒能够诱发抗至少两个型别的HPV(例如，HPV11和HPV6)的中和抗体，从而可用于预防所述至少两个型别的HPV感染以及由所述感染所导致的疾病例如宫颈癌和尖锐湿疣。上述蛋白和病毒样颗粒用于制备药物组合物或疫苗的用途，所述药物组合物或疫苗可用于预防所述至少两个型别的HPV感染以及由所述感染所导致的疾病例如宫颈癌和尖锐湿疣。

Description

一种人乳头瘤病毒11型L1蛋白的突变体 技术领域
本发明涉及分子病毒学和免疫学领域。具体地，本发明涉及一种突变的HPV11L1蛋白(或其变体)，其编码序列和制备方法，以及包含其的病毒样颗粒，所述蛋白(或其变体)和病毒样颗粒能够诱发抗至少两个型别的HPV(例如，HPV11和HPV6)的中和抗体，从而可用于预防所述至少两个型别的HPV感染以及由所述感染所导致的疾病例如宫颈癌和尖锐湿疣。本发明还涉及上述蛋白和病毒样颗粒用于制备药物组合物或疫苗的用途，所述药物组合物或疫苗可用于预防所述至少两个型别的HPV感染以及由所述感染所导致的疾病例如宫颈癌和尖锐湿疣。
背景技术
人乳头瘤病毒(Human Papillomavirus，HPV)主要引起皮肤和粘膜的疣状病变。根据其与肿瘤发生的关系，HPV可分为高危型与低危型，其中高危型的HPV感染被证实是诱发包括女性宫颈癌在内的生殖器癌症的主要原因；低危型则主要引起尖锐湿疣。预防与控制HPV感染的最有效方式是接种HPV疫苗，特别是针对能引起宫颈癌的高危型HPV的疫苗。
HPV的主要衣壳蛋白L1具有自组装为空心病毒样颗粒(Virus-Like Particle，VLP)的特性。HPV VLP是由72个主要衣壳蛋白L1的五聚体构成的20面体立体对称结构(Doorbar，J.and P.H.Gallimore.1987.J Virol，61(9)：2793-9)。HPV VLP的结构与天然HPV高度相似，保留了天然病毒的绝大多数中和表位，可诱导高滴度的中和抗体(Kirnbauer，R.，F.Booy，et al.1992Proc Natl Acad Sci U S A 89(24)：12180-4)。
然而，现有的研究显示，HPV VLP主要诱导针对同型HPV的中和抗体，产生针对同型HPV的保护性免疫，而仅在一些同源性高的型别之间存在低的交叉保护作用(Sara L.Bissett，Giada Mattiuzzo，et al.2014Vaccine.32：6548-6555)。因此，现有的HPV疫苗的保护范围非常有限。通常，一个型别的HPV VLP只能用于预防该型别的HPV感染。在这种情况下，如果要扩大HPV疫苗的保护范围，那就只能在疫苗中增加更多型别的HPV VLP。目前已上市的HPV疫苗，包括Merck公司的
Figure PCTCN2016108349-appb-000001
(其为针对 HPV16，18，6和11的四价疫苗)，GSK公司的
Figure PCTCN2016108349-appb-000002
(其为针对HPV16，18的二价疫苗)和Merck公司的
Figure PCTCN2016108349-appb-000003
(其为九价疫苗)，均是通过混合多个型别的HPV VLP而制成。然而，这种方案将导致HPV疫苗的生产成本大大提高，并且可能因为免疫剂量的增加而导致潜在的安全性问题。
因此，本领域需要开发能够诱导针对多个型别的HPV的保护性中和抗体的HPV病毒样颗粒，以更经济、有效地预防多个型别的HPV感染和由此导致的疾病例如宫颈癌和尖锐湿疣。
发明内容
本发明至少部分基于发明人的下述出人意料的发现：将人乳头瘤病毒(HPV)11型L1蛋白中的特定区段置换为第二型别的HPV(例如HPV6)L1蛋白的相应区段后，所获得的突变的HPV11L1蛋白能够诱导机体产生针对HPV11和第二型别的HPV(例如HPV6)的高滴度中和抗体，其保护效果与混合的HPV11VLP和第二型别的HPV VLP相当，并且针对HPV11的保护效果与单独的HPV11VLP相当，且针对第二型别的HPV(例如HPV6)的保护效果与单独的第二型别的HPV VLP相当。
因此，在一个方面，本发明提供了一种突变的HPV11L1蛋白或其变体，其中，所述突变的HPV11L1蛋白与野生型HPV11L1蛋白相比，具有下述突变：
(1)N端截短了3-6个氨基酸，例如3个、4个、5个或6个氨基酸；和
(2)(a)位于野生型HPV11L1蛋白第170-179位的氨基酸残基被替换为第二型别的野生型HPV L1蛋白的相应位置的氨基酸残基；或
(b)位于野生型HPV11L1蛋白第346-351位的氨基酸残基被替换为第二型别的野生型HPV L1蛋白的相应位置的氨基酸残基；或
(c)位于野生型HPV11L1蛋白第119-140位的氨基酸残基被替换为第二型别的野生型HPV L1蛋白的相应位置的氨基酸残基；
并且，所述变体与所述突变的HPV11L1蛋白相异仅在于一个或几个(例如，1个、2个、3个、4个、5个、6个、7个、8个或9个)氨基酸的置换(优选保守置换)、添加或缺失，且保留了所述突变的HPV11L1蛋白的功能，即，能够诱导针对至少两个型别的HPV(例如，HPV11和HPV6)的中和抗体。
在某些优选的实施方案中，所述突变的HPV11L1蛋白与野生型HPV11L1蛋白相比，N端截短了3个、4个、5个或6个氨基酸。
在某些优选的实施方案中，所述突变的HPV11L1蛋白与野生型HPV11L1蛋白相比，N端截短了4个氨基酸。
在某些优选的实施方案中，所述第二型别的野生型HPV为HPV6。在某些优选的实施方案中，(2)(a)中所述的相应位置的氨基酸残基为野生型HPV6L1蛋白第169-178位的氨基酸残基。
在某些优选的实施方案中，所述第二型别的野生型HPV为HPV6。在某些优选的实施方案中，(2)(b)中所述的相应位置的氨基酸残基为野生型HPV6L1蛋白第345-350位的氨基酸残基。
在某些优选的实施方案中，所述第二型别的野生型HPV为HPV6。在某些优选的实施方案中，(2)(c)中所述的相应位置的氨基酸残基为野生型HPV6L1蛋白第119-139位的氨基酸残基。
在某些优选的实施方案中，所述野生型HPV11L1蛋白具有如SEQ ID NO：1所示的氨基酸序列。
在某些优选的实施方案中，所述野生型HPV6L1蛋白具有如SEQ ID NO：2所示的氨基酸序列。
在某些优选的实施方案中，所述野生型HPV6L1蛋白第169-178位的氨基酸残基的序列如SEQ ID NO：35所示。
在某些优选的实施方案中，所述野生型HPV6L1蛋白第345-350位的氨基酸残基的序列如SEQ ID NO：36所示。
在某些优选的实施方案中，所述野生型HPV6L1蛋白第119-139位的氨基酸残基的序列如SEQ ID NO：37所示。
在某些优选的实施方案中，所述突变的HPV11L1蛋白具有选自下列的氨基酸序列：SEQ ID NO：6、7和9。
在另一个方面，本发明提供了一种分离的核酸，其编码如上所述的突变的HPV11L1蛋白或其变体。在另一个方面，本发明提供了一种载体，其包含所述分离的核酸。在某些优选的实施方案中，本发明的分离的核酸具有选自下列的核苷酸序列：SEQ ID NO： 13、14和16。
可用于插入目的多核苷酸的载体是本领域公知的，包括但不限于克隆载体和表达载体。在一个实施方案中，载体是例如质粒，粘粒，噬菌体等等。
在另一个方面，本发明还涉及包含上述分离的核酸或载体的宿主细胞。此类宿主细胞包括但不限于，原核细胞例如大肠杆菌细胞，以及真核细胞例如酵母细胞，昆虫细胞，植物细胞和动物细胞(如哺乳动物细胞，例如小鼠细胞、人细胞等)。本发明的宿主细胞还可以是细胞系，例如293T细胞。
在另一个方面，本发明涉及一种HPV病毒样颗粒，其中该病毒样颗粒含有本发明的突变的HPV11L1蛋白或其变体，或者由本发明的突变的HPV11L1蛋白或其变体组成或形成。
在某些优选的实施方案中，本发明的HPV病毒样颗粒包含突变的HPV11L1蛋白，其与野生型HPV11L1蛋白相比，N端截短了3-6个氨基酸，例如3个、4个、5个或6个氨基酸，并且位于野生型HPV11L1蛋白第170-179位的氨基酸残基被替换为野生型HPV6L1蛋白第169-178位的氨基酸残基。
在某些优选的实施方案中，本发明的HPV病毒样颗粒包含突变的HPV11L1蛋白，其与野生型HPV11L1蛋白相比，N端截短了3-6个氨基酸，例如3个、4个、5个或6个氨基酸，并且位于野生型HPV11L1蛋白第346-351位的氨基酸残基被替换为野生型HPV6L1蛋白第345-350位的氨基酸残基。
在某些优选的实施方案中，本发明的HPV病毒样颗粒包含突变的HPV11L1蛋白，其与野生型HPV11L1蛋白相比，N端截短了3-6个氨基酸，例如3个、4个、5个或6个氨基酸，并且位于野生型HPV11L1蛋白第119-140位的氨基酸残基被替换为野生型HPV6L1蛋白第119-139位的氨基酸残基。
在一个特别优选的实施方案中，本发明的HPV病毒样颗粒包含突变的HPV11L1蛋白，其具有SEQ ID NO：6、7或9所示的序列。
在另一个方面，本发明还涉及包含上述突变的HPV11L1蛋白或其变体，或上述分离的核酸或载体或宿主细胞或HPV病毒样颗粒的组合物。在某些优选的实施方案中，所述组合物包含本发明的突变的HPV11L1蛋白或其变体。在某些优选的实施方案中，所 述组合物包含本发明的HPV病毒样颗粒。
在另一个方面，本发明还涉及一种药物组合物或疫苗，其包含本发明的HPV病毒样颗粒，任选地还包含药学可接受的载体和/或赋形剂。本发明的药物组合物或疫苗可以用于预防HPV感染或由HPV感染所导致的疾病例如宫颈癌和尖锐湿疣。
在某些优选的实施方案中，所述HPV病毒样颗粒以预防HPV感染或由HPV感染导致的疾病的有效量存在。在某些优选的实施方案中，所述HPV感染是一个或多个型别的HPV感染(例如，HPV11感染和/或HPV6感染)。在某些优选的实施方案中，所述由HPV感染所导致的疾病选白宫颈癌和尖锐湿疣。
本发明的药物组合物或疫苗可通过本领域公知的方法进行施用，例如但不限于通过口服或者注射进行施用。在本发明中，特别优选的施用方式是注射。
在某些优选的实施方案中，本发明的药物组合物或疫苗以单位剂量形式进行施用。例如但不意欲限定本发明，每单位剂量中包含的HPV病毒样颗粒的量为5μg-80μg，优选20μg-40μg。
在另一个方面，本发明涉及一种制备如上所述的突变的HPV11L1蛋白或其变体的方法，其包括，在宿主细胞中表达所述突变的HPV11L1蛋白或其变体，然后从所述宿主细胞的培养物中回收所述突变的HPV11L1蛋白或其变体。
在某些优选的实施方案中，所述宿主细胞为大肠杆菌。
在某些优选的实施方案中，所述方法包括步骤：在大肠杆菌中表达所述突变的HPV11L1蛋白或其变体，然后从所述大肠杆菌的裂解上清中纯化得到所述突变的HPV11L1蛋白或其变体。在某些优选的实施方案中，通过色谱法(例如，阳离子交换色谱，羟基磷灰石色谱和/或疏水相互作用色谱)，从所述大肠杆菌的裂解上清中回收所述突变的HPV11L1蛋白或其变体。
在另一个方面，本发明涉及一种制备疫苗的方法，其包括将本发明的HPV病毒样颗粒与药学可接受的载体和/或赋形剂混合。
在另一个方面，本发明涉及一种预防HPV感染或由HPV感染所导致的疾病的方法，其包括将预防有效量的根据本发明的HPV病毒样颗粒或药物组合物或疫苗施用给受试者。在一个优选的实施方案中，所述HPV感染是一个或多个型别的HPV感染(例如，HPV11 感染和/或HPV6感染)。在另一个优选的实施方案中，所述由HPV感染所导致的疾病包括但不限于，宫颈癌和尖锐湿疣。在另一个优选的实施方案中，所述受试者是哺乳动物，例如人。
在另一个方面，还涉及根据本发明的突变的HPV11L1蛋白或其变体或HPV病毒样颗粒在制备药物组合物或疫苗中的用途，所述药物组合物或疫苗用于预防HPV感染或由HPV感染所导致的疾病。在一个优选的实施方案中，所述HPV感染是一个或多个型别的HPV感染(例如，HPV11感染和/或HPV6感染)。在另一个优选的实施方案中，所述由HPV感染所导致的疾病包括但不限于，宫颈癌和尖锐湿疣。
本发明中相关术语的说明及解释
在本发明中，除非另有说明，否则本文中使用的科学和技术名词具有本领域技术人员所通常理解的含义。并且，本文中所用的细胞培养、分子遗传学、核酸化学、免疫学实验室操作步骤均为相应领域内广泛使用的常规步骤。同时，为了更好地理解本发明，下面提供相关术语的定义和解释。
根据本发明，术语“第二型别的野生型HPV”是指，不同于HPV11的另一型别的野生型HPV。在本发明中，第二型别的野生型HPV优选为野生型HPV6。
根据本发明，表述“相应位置”是指，当对序列进行最优比对时，即当序列进行比对以获得最高百分数同一性时，进行比较的序列中的等同位置。
根据本发明，术语“野生型HPV11L1蛋白”是指，天然存在于人乳头瘤病毒11型(HPV11)中的主要衣壳蛋白L1。野生型HPV11L1蛋白的序列是本领域公知的，并且可参见各种公共数据库(例如NCBI数据库登录号M14119.1，AF335603.1，AF335602.1等所编码的HPV11L1蛋白)。
在本发明中，当提及野生型HPV11L1蛋白的氨基酸序列时，参照SEQ ID NO：1所示的序列来进行描述。例如，表述“野生型HPV11L1蛋白的第170-179位氨基酸残基”是指，SEQ ID NO：1所示的多肽的第170-179位氨基酸残基。然而，本领域技术人员理解，野生型HPV11可包括多种分离株，并且各种分离株的L1蛋白的氨基酸序列之间可能存在着差异。进一步，本领域技术人员理解，尽管可能存在着序列差异，但是HPV11的不同分离株的L1蛋白在氨基酸序列上具有极高的同一性(通常高于95％，例如高于96％，高于97％，高于98％，或高于99％)，并且具有实质上相同的生物学功能。因此， 在本发明中，术语“野生型HPV11L1蛋白”不仅包括SEQ ID NO：1所示的蛋白，而且应包括各种HPV11分离株的L1蛋白(例如NCBI数据库登录号M14119.1，AF335603.1，AF335602.1等所编码的HPV11L1蛋白)。并且，当描述野生型HPV11L1蛋白的序列片段时，其不仅包括SEQ ID NO：1的序列片段，还包括各种HPV11分离株的L1蛋白中的相应序列片段。例如，表述“野生型HPV11L1蛋白的第170-179位氨基酸残基”包括，SEQ ID NO：1的第170-179位氨基酸残基，以及各种HPV11分离株的L1蛋白中的相应片段。
根据本发明，术语“野生型HPV6L1蛋白”是指，天然存在于人乳头瘤病毒6型(HPV6)中的主要衣壳蛋白L1。野生型HPV6L1蛋白的序列是本领域公知的，并且可参见各种公共数据库(例如NCBI数据库登录号AF067042.1，AF092932.1，L41216.1，X00203.1等所编码的HPV6L1蛋白)。
在本发明中，当提及野生型HPV6L1蛋白的氨基酸序列时，参照SEQ ID NO：2所示的序列来进行描述。例如，表述“野生型HPV6L1蛋白的第169-178位氨基酸残基”是指，SEQ ID NO：2所示的多肽的第169-178位氨基酸残基。然而，本领域技术人员理解，野生型HPV6可包括多种分离株，并且各种分离株的L1蛋白的氨基酸序列之间可能存在着差异。进一步，本领域技术人员理解，尽管可能存在着序列差异，但是HPV6的不同分离株的L1蛋白在氨基酸序列上具有极高的同一性(通常高于95％，例如高于96％，高于97％，高于98％，或高于99％)，并且具有实质上相同的生物学功能。因此，在本发明中，术语“野生型HPV6L1蛋白”不仅包括SEQ ID NO：2所示的蛋白，而且应包括各种HPV6分离株的L1蛋白(例如NCBI数据库登录号AF067042.1，AF092932.1，L41216.1，X00203.1等所编码的HPV6L1蛋白)。并且，当描述野生型HPV6L1蛋白的序列片段时，其不仅包括SEQ ID NO：2的序列片段，还包括各种HPV6分离株的L1蛋白中的相应序列片段。例如，表述“野生型HPV6L1蛋白的第169-178位氨基酸残基”包括，SEQ ID NO：2的第169-178位氨基酸残基，以及各种HPV6分离株的L1蛋白中的相应片段。
根据本发明，表述“相应序列片段”或“相应片段”是指，当对序列进行最优比对时，即当序列进行比对以获得最高百分数同一性时，进行比较的序列中位于等同位置的片段。
根据本发明，表述“N端截短了X个氨基酸”是指，用起始密码子(用于起始蛋白 质翻译)编码的甲硫氨酸残基置换蛋白质N末端的第1-X位氨基酸残基。例如，N端截短了4个氨基酸的HPV11L1蛋白是指，用起始密码子编码的甲硫氨酸残基置换野生型HPV11L1蛋白N末端的第1-4位氨基酸残基所获得的蛋白质。
根据本发明，术语“变体”是指这样的蛋白，其氨基酸序列与本发明的突变的HPV11L1蛋白(如SEQ ID NO：6、7或9所示的蛋白)的氨基酸序列相比，具有一个或几个(例如，1个、2个、3个、4个、5个、6个、7个、8个或9个)氨基酸的置换(优选保守置换)、添加或缺失，或者具有至少90％，95％，96％，97％，98％，或99％的同一性，并且其保留了所述突变的HPV11L1蛋白的功能。在本发明中，术语“突变的HPV11L1蛋白的功能”是指：能够诱导机体产生针对至少两个型别的HPV(例如，HPV11和HPV6)的中和抗体。术语“同一性”是对核苷酸序列或氨基酸序列的相似性的量度。通常将序列排列起来，以获得最大限度的匹配。“同一性”本身具有本领域公知的意义并且可用公开的算法(例如BLAST)来计算。
根据本发明，术语“同一性”用于指两个多肽之间或两个核酸之间序列的匹配情况。当两个进行比较的序列中的某个位置都被相同的碱基或氨基酸单体亚单元占据时(例如，两个DNA分子的每一个中的某个位置都被腺嘌呤占据，或两个多肽的每一个中的某个位置都被赖氨酸占据)，那么各分子在该位置上是同一的。两个序列之间的“百分数同一性”是由这两个序列共有的匹配位置数目除以进行比较的位置数目×100的函数。例如，如果两个序列的10个位置中有6个匹配，那么这两个序列具有60％的同一性。例如，DNA序列CTGACT和CAGGTT共有50％的同一性(总共6个位置中有3个位置匹配)。通常，在将两个序列比对以产生最大同一性时进行比较。这样的比对可通过使用，例如，可通过计算机程序例如Align程序(DNAstar，Inc)方便地进行的Needleman等人(1970)J.Mol.Biol.48：443-453的方法来实现。还可使用已整合入ALIGN程序(版本2.0)的E.Meyers和W.Miller(Comput.Appl Biosci.，4：11-17(1988))的算法，使用PAM120权重残基表(weight residue table)、12的缺口长度罚分和4的缺口罚分来测定两个氨基酸序列之间的百分数同一性。此外，可使用已整合入GCG软件包(可在www.gcg.com上获得)的GAP程序中的Needleman和Wunsch(J MoI Biol.48：444-453(1970))算法，使用Blossum 62矩阵或PAM250矩阵以及16、14、12、10、8、6或4的缺口权重(gap weight)和1、2、3、4、5或6的长度权重来测定两个氨基酸序列之间的百分数同一性。
如本文中使用的，术语“保守置换”意指不会不利地影响或改变包含氨基酸序列的蛋白/多肽的必要特性的氨基酸置换。例如，可通过本领域内已知的标准技术例如定点诱变和PCR介导的诱变引入保守置换。保守氨基酸置换包括用具有相似侧链的氨基酸残基替代氨基酸残基的置换，例如用在物理学上或功能上与相应的氨基酸残基相似(例如具有相似大小、形状、电荷、化学性质，包括形成共价键或氢键的能力等)的残基进行的置换。已在本领域内定义了具有相似侧链的氨基酸残基的家族。这些家族包括具有碱性侧链(例如，赖氨酸、精氨酸和组氨酸)、酸性侧链(例如天冬氨酸、谷氨酸)、不带电荷的极性侧链(例如甘氨酸、天冬酰胺、谷氨酰胺、丝氨酸、苏氨酸、酪氨酸、半胱氨酸、色氨酸)、非极性侧链(例如丙氨酸、缬氨酸、亮氨酸、异亮氨酸、脯氨酸、苯丙氨酸、甲硫氨酸)、β分支侧链(例如，苏氨酸、缬氨酸、异亮氨酸)和芳香族侧链(例如，酪氨酸、苯丙氨酸、色氨酸、组氨酸)的氨基酸。因此，保守置换通常是指，用来自相同侧链家族的另一个氨基酸残基替代相应的氨基酸残基。鉴定氨基酸保守置换的方法在本领域内是熟知的(参见，例如，Brummell等人，Biochem.32：1180-1187(1993)；Kobayashi等人Protein Eng.12(10)：879-884(1999)；和Burks等人Proc.Natl Acad.Set USA 94：412-417(1997)，其通过引用并入本文)。
根据本发明，术语“大肠杆菌表达系统”是指由大肠杆菌(菌株)与载体组成的表达系统，其中大肠杆菌(菌株)来源于市场上可得到的菌株，例如但不限于：ER2566，BL21(DE3)，B834(DE3)，BLR(DE3)。
根据本发明，术语“载体(vector)”是指，可将多核苷酸插入其中的一种核酸运载工具。当载体能使插入的多核苷酸所编码的蛋白获得表达时，载体称为表达载体。载体可以通过转化，转导或者转染导入宿主细胞，使其携带的遗传物质元件在宿主细胞中获得表达。载体是本领域技术人员公知的，包括但不限于：质粒；噬菌体；柯斯质粒等等。
根据本发明，术语“药学可接受的载体和/或赋形剂”是指在药理学和/或生理学上与受试者和活性成分相容的载体和/或赋形剂，其是本领域公知的(参见例如Remington’s Pharmaceutical Sciences.Edited by Gennaro AR，19th ed.Pennsylvania：Mack Publishing Company，1995)，并且包括但不限于：pH调节剂，表面活性剂，佐剂，离子强度增强剂。例如，pH调节剂包括但不限于磷酸盐缓冲液；表面活性剂包括但不限于阳离子，阴离子或者非离子型表面活性剂，例如Tween-80；佐剂 包括但不限于铝佐剂(例如氢氧化铝)，弗氏佐剂(例如完全弗氏佐剂)；离子强度增强剂包括但不限于氯化钠。
根据本发明，术语“有效量”是指能够有效实现预期目的的量。例如，预防疾病(例如HPV感染)有效量是指，能够有效预防，阻止，或延迟疾病(例如HPV感染)的发生的量。测定这样的有效量在本领域技术人员的能力范围之内。
根据本发明，术语“色谱层析”包括但不限于：离子交换色谱(例如阳离子交换色谱)、疏水相互作用色谱、吸附层析法(例如羟基磷灰石色谱)、凝胶过滤(凝胶排阻)层析、亲和层析法。
根据本发明，术语“裂解上清”是指通过下述步骤所产生的溶液：将宿主细胞(例如大肠杆菌)在裂解液中破碎，然后将含有经破碎的宿主细胞的裂解液中的不溶物去除。各种裂解液是本领域技术人员公知的，包括但不限于Tris缓冲液，磷酸盐缓冲液，HEPES缓冲液，MOPS缓冲液等等。此外，可通过本领域技术人员熟知的各种方法来实现宿主细胞的破碎，包括但不限于匀浆器破碎、均质机破碎、超声波处理、研磨、高压挤压、溶菌酶处理等等。去除裂解液中的不溶物的方法也是本领域技术人员公知的，包括但不限于过滤和离心。
发明的有益效果
研究表明，虽然HPV11和其他型别的HPV(例如HPV6)之间存在一定的交叉保护，但是这种交叉保护的能力很低，通常低于自身型别的VLP的保护水平的百分之一，甚至低于千分之一。因此，对于接种了HPV11疫苗的受试者来说，其感染其他型别的HPV(例如HPV6)的风险依然很高。
本发明提供了一种突变的HPV11L1蛋白以及由其形成的HPV病毒样颗粒。本发明的HPV病毒样颗粒能够在HPV11和其他型别的HPV(例如HPV6)之间提供显著的交叉保护能力。特别地，在同等免疫剂量下，本发明的HPV病毒样颗粒能够诱发机体产生针对至少两个型别的HPV(例如，HPV11和HPV6)的高滴度中和抗体，并且其效果与多个型别的HPV VLP的混合物(例如，HPV11VLP和HPV6VLP的混合物)相当。因此，本发明的HPV病毒样颗粒能够用于同时预防至少两个型别的HPV(例如，HPV11和HPV6)的感染以及与此相关的疾病，具有显著的有利技术效果。这在扩大HPV疫苗的保护范围和降低HPV疫苗的生产成本等方面具有特别显著的优势。
下面将结合附图和实施例对本发明的实施方案进行详细描述，但是本领域技术人员将理解，下列附图和实施例仅用于说明本发明，而不是对本发明的范围的限定。根据附图和优选实施方案的下列详细描述，本发明的各种目的和有利方面对于本领域技术人员来说将变得显然。
附图说明
图1显示了实施例1中经纯化的突变蛋白的SDS聚丙烯酰胺凝胶电泳的结果。泳道M：蛋白分子量标记；泳道1：HPV11N4(N端截短了4个氨基酸的HPV11L1蛋白)；泳道2：H11N4-6T1；泳道3：H11N4-6T2；泳道4：H11N4-6T3；泳道5：H11N4-6T4；泳道6：H11N4-6T5。结果显示，经过色谱纯化后，蛋白H11N4-6T1、H11N4-6T2、H11N4-6T3、H11N4-6T4和H11N4-6T5的纯度达到95％以上。
图2A-2F显示了包含蛋白HPV11N4、H11N4-6T1、H11N4-6T2、H11N4-6T3、H11N4-6T4和H11N4-6T5的样品的分子筛层析分析的结果。图2A：HPV11N4；图2B：H11N4-6T1；图2C：H11N4-6T2；图2D：H11N4-6T3；图2E：H11N4-6T4；图2F：H11N4-6T5。结果显示，包含H11N4-6T1、H11N4-6T2、H11N4-6T3、H11N4-6T4和H11N4-6T5的样品最先出现的蛋白峰均在12min左右，与HPV11N4VLP相当。这表明，上述突变蛋白组装均可组装成VLP。
图3A-3F显示了HPV11N4VLP、H11N4-6T1VLP、H11N4-6T2VLP、H11N4-6T3VLP、H11N4-6T4VLP和H11N4-6T5VLP的沉降速率分析的结果。图3A，HPV11N4VLP；图3B，H11N4-6T1VLP；图3C，H11N4-6T2VLP；图3D，H11N4-6T3VLP；图3E，H11N4-6T4VLP；图3F，H11N4-6T5VLP。结果显示，H11N4-6T1VLP、H11N4-6T2VLP、H11N4-6T3VLP、H11N4-6T4VLP和H11N4-6T5VLP的沉降系数分别为140S、138S、111S、139S和139S。这表明，如上制备的5种突变的HPV11L1蛋白各自能够组装成大小、形态与野生型VLP(HPV11N4VLP，136.3S)相似的病毒样颗粒。
图4A-4F显示了各种VLP样品的透射电镜观察结果(放大倍数为100,000倍，Bar＝0.1μm)。图4A，HPV11N4VLP；图4B，H11N4-6T1VLP；图4C，H11N4-6T2VLP；图4D，H11N4-6T3VLP；图4E，H11N4-6T4VLP；图4F，H11N4-6T5VLP。结果显示，H11N4-6T1、H11N4-6T2、H11N4-6T3、H11N4-6T4和H11N4-6T5与HPV11N4类似，都能够组装成半径为25nm左右的VLP。
图5A-5F显示了HPV11N4、H11N4-6T1、H11N4-6T2、H11N4-6T3、H11N4-6T4和H11N4-6T5所形成的VLP的热稳定性评价的结果。图5A，HPV11N4VLP；图5B，H11N4-6T1VLP；图5C，H11N4-6T2VLP；图5D，H11N4-6T3VLP；图5E，H11N4-6T4VLP；图5F，H11N4-6T5VLP。结果显示，各个蛋白所形成的VLP均具有极高的热稳定性。
图6A-6D显示了使用冷冻电镜观察H11N4-6T3VLP和H11N4-6T5VLP并解析其结构而获得的结果；其中，图6A和图6C分别显示了H11N4-6T3VLP和H11N4-6T5VLP的冷冻电镜观察结果；图6B和图6D分别显示了利用冷冻电镜解析的H11N4-6T3VLP和H11N4-6T5VLP的三维结构，其分辨率分别为
Figure PCTCN2016108349-appb-000004
和
Figure PCTCN2016108349-appb-000005
图7显示了实验组H11N4-6T1、H11N4-6T2、H11N4-6T3、H11N4-6T4和H11N4-6T5与对照组HPV11N4VLP、HPV6N5VLP和混合的HPV11/HPV6VLP在小鼠体内的免疫保护性的评价结果。结果显示，H11N4-6T3VLP和H11N4-6T5VLP各自可在小鼠体内诱导高滴度的针对HPV11和HPV6的中和抗体；并且其针对HPV11的保护效果与单独的HPV11N4VLP、混合的HPV11/HPV6VLP相当，且显著高于单独的HPV6N5VLP；并且其针对HPV6的保护效果与单独的HPV6N5VLP、混合的HPV11/HPV6VLP相当，且显著高于单独的HPV11N4VLP。H11N4-6T2VLP也可在小鼠体内诱导高滴度的针对HPV11和HPV6的中和抗体，但其诱导抗HPV6中和抗体的能力弱于H11N4-6T3VLP和H11N4-6T5VLP。这些结果表明，H11N4-6T2VLP、H11N4-6T3VLP和H11N4-6T5VLP可用作预防HPV11感染和HPV6感染的有效疫苗，可用于代替含有HPV11VLP和HPV6VLP的混合疫苗。
图8A-8C显示了用H11N4-6T3VLP和H11N4-6T5VLP免疫小鼠后小鼠血清中的中和抗体滴度的评价结果。图8A：铝佐剂组1(免疫剂量为10μg，使用铝佐剂)；图8B：铝佐剂组2(免疫剂量为1μg，使用铝佐剂)；图8C：铝佐剂组3(免疫剂量为0.1μg，使用铝佐剂)。结果显示，H11N4-6T3VLP和H11N4-6T5VLP各自能诱导小鼠产生高滴度的针对HPV11的中和抗体，其保护效果与同剂量的单独的HPV11N4VLP、混合的HPV11/HPV6VLP相当，且显著优于同剂量的单独的HPV6N5VLP；并且其能诱导小鼠产生高滴度的针对HPV6的中和抗体，其保护效果与同剂量的单独的HPV6N5VLP、混合的HPV11/HPV6VLP相当，且显著优于同剂量的单独的HPV11N4VLP。这表明，H11N4-6T3VLP和H11N4-6T5VLP各自对HPV11和HPV6具有良好的交叉免疫原性和交叉保护性。
图9显示了用H11N4-6T3VLP和H11N4-6T5VLP免疫食蟹猴后，食蟹猴血清中的中和抗体滴度的评价结果。结果显示，H11N4-6T3VLP和H11N4-6T5VLP各自能诱导食蟹 猴产生高滴度的针对HPV11和HPV6的中和抗体，其保护效果与混合的HPV11/HPV6VLP相当。这表明，H11N4-6T3VLP和H11N4-6T5VLP各自对HPV11和HPV6具有良好的交叉免疫原性和交叉保护性。
序列信息
本发明涉及的部分序列的信息提供于下面的表1中。
表1：序列的描述
SEQ ID NO： 描述
1 野生型HPV11L1蛋白
2 野生型HPV6L1蛋白
3 N端截短了4个氨基酸的HPV11L1蛋白，HPV11N4
4 N端截短了5个氨基酸的HPV6L1蛋白，HPV6N5
5 含有HPV6L1蛋白的区段1的突变的HPV11L1蛋白，H11N4-6T1
6 含有HPV6L1蛋白的区段2的突变的HPV11L1蛋白，H11N4-6T2
7 含有HPV6L1蛋白的区段3的突变的HPV11L1蛋白，H11N4-6T3
8 含有HPV6L1蛋白的区段4的突变的HPV11L1蛋白，H11N4-6T4
9 含有HPV6L1蛋白的区段5的突变的HPV11L1蛋白，H11N4-6T5
10 编码SEQ ID NO：3的DNA序列
11 编码SEQ ID NO：4的DNA序列
12 编码SEQ ID NO：5的DNA序列
13 编码SEQ ID NO：6的DNA序列
14 编码SEQ ID NO：7的DNA序列
15 编码SEQ ID NO：8的DNA序列
16 编码SEQ ID NO：9的DNA序列
35 野生型HPV6L1蛋白第169-178位的氨基酸残基的序列
36 野生型HPV6L1蛋白第345-350位的氨基酸残基的序列
37 野生型HPV6L1蛋白第119-139位的氨基酸残基的序列
序列1(SEQ ID NO：1)：
Figure PCTCN2016108349-appb-000006
序列2(SEQ ID NO：2)：
Figure PCTCN2016108349-appb-000007
序列3(SEQ ID NO：3)：
Figure PCTCN2016108349-appb-000008
序列4(SEQ ID NO：4)：
Figure PCTCN2016108349-appb-000009
序列5(SEQ ID NO：5)：
Figure PCTCN2016108349-appb-000010
序列6(SEQ ID NO：6)：
Figure PCTCN2016108349-appb-000011
序列7(SEQ ID NO：7)：
Figure PCTCN2016108349-appb-000012
序列8(SEQ ID NO：8)：
Figure PCTCN2016108349-appb-000013
序列9(SEQ ID NO：9)：
Figure PCTCN2016108349-appb-000014
序列10(SEQ ID NO：10)：
Figure PCTCN2016108349-appb-000015
序列11(SEQ ID NO：11)：
Figure PCTCN2016108349-appb-000016
Figure PCTCN2016108349-appb-000017
序列12(SEQ ID NO：12)：
Figure PCTCN2016108349-appb-000018
序列13(SEQ ID NO：13)：
Figure PCTCN2016108349-appb-000019
序列14(SEQ ID NO：14)：
Figure PCTCN2016108349-appb-000020
Figure PCTCN2016108349-appb-000021
序列15(SEQ ID NO：15)：
Figure PCTCN2016108349-appb-000022
序列16(SEQ ID NO：16)：
Figure PCTCN2016108349-appb-000023
序列35(SEQ ID NO：35)：
Figure PCTCN2016108349-appb-000024
序列36(SEQ ID NO：36)：
Figure PCTCN2016108349-appb-000025
序列37(SEQ ID NO：37)：
Figure PCTCN2016108349-appb-000026
具体实施方式
现参照下列意在举例说明本发明(而非限定本发明)的实施例来描述本发明。
除非特别指明，本发明中所使用的分子生物学实验方法和免疫检测法，基本上参照J.Sambrook等人，分子克隆：实验室手册，第2版，冷泉港实验室出版社，1989，以及F.M.Ausubel等人，精编分子生物学实验指南，第3版，John Wiley&Sons，Inc.，1995中所述的方法进行；限制性内切酶的使用依照产品制造商推荐的条件。本领域技术人员知晓，实施例以举例方式描述本发明，且不意欲限制本发明所要求保护的范围。
实施例1.突变的HPV11L1蛋白的表达与纯化
表达载体的构建
采用多点突变PCR反应来构建编码含有来源于HPV6L1蛋白的特定区段的突变的HPV11L1蛋白(H11N4-6T1)的表达载体，其中，所使用的初始模板为pT0-T7-HPV11N4C质粒(其编码N端截短了4个氨基酸的HPV11L1蛋白；在表2中简写为11L1N4)。用于各个PCR反应的模板和引物见表2，并且，PCR反应的扩增条件设为：94℃变性10分钟；25个循环的(94℃变性50秒，指定温度退火一定时间，72℃延伸7分30秒)；最后72℃延伸10分钟。所使用的PCR引物的具体序列列于表3。
向扩增产物(50μL)中加入2μL DpnI限制性内切酶，并在37℃温育60min。取10μL酶切产物，用于转化40μL以氯化钙法制备的感受态大肠杆菌ER2566(购自新英格兰生物实验室公司)。将经转化的大肠杆菌涂布于含卡那霉素(终浓度25mg/mL，下同)的固体LB培养基(LB培养基成分：10g/L蛋白胨，5g/L酵母粉，10g/L氯化钠，下同)，并在37℃静置培养10-12小时，直至单菌落清晰可辨。挑取单菌落至含有4mL液体LB培养基(含卡那霉素)的试管中，并在37℃220转/分钟下振荡培养10小时。随后，取1mL菌液于-70℃保存。从大肠杆菌中提取质粒，并利用T7引物对质粒中插入 的目的片段的核苷酸序列进行测序。测序结果显示，所构建的质粒(表达载体)中插入的目的片段的核苷酸序列为SEQ ID NO：12，其编码的氨基酸序列为SEQ ID NO：5(所对应的蛋白分别命名为H11N4-6T1)。突变蛋白H11N4-6T1与HPV11N4的区别在于：位于野生型HPV11L1蛋白第49-63位的氨基酸残基被替换为野生型HPV6L1蛋白第49-63位的氨基酸残基。
采用Gibson装配(Gibson DG，Young L，Chuang RY，Venter JC，Hutchison CA，Smith HO.Enzymatic assembly of DNA molecules up to several hundred kilobases.Nat Methods.2009；6：343-5.doi：10.1038/nmeth.1318)来构建编码其他的突变HPV11L1蛋白的表达载体，所述突变的HPV11L1蛋白含有来源于HPV6L1的特定区段。简言之，首先采用PCR反应来获得一个包含突变的短片段和一个不包含突变的长片段，然后再采用Gibson装配体系将这两个片段连接成环。所使用的初始模板包括pT0-T7-HPV11N4C质粒和pT0-T7-HPV6N5C质粒(其编码N端截短了5个氨基酸的HPV6L1蛋白；在表2中简写为6L1N5)。用于各个PCR反应的模板和引物见表2，并且，用于扩增短片段的PCR反应的扩增条件设为：94℃变性10分钟；25个循环的(94℃变性50秒，指定温度退火一定时间，72℃延伸1分钟)；最后72℃延伸10分钟。用于扩增长片段的PCR反应的扩增条件设为：94℃变性10分钟；25个循环的(94℃变性50秒，指定温度退火一定时间，72℃延伸7分30秒)；最后72℃延伸10分钟。所使用的PCR引物的具体序列列于表3。将扩增产物进行电泳，随后使用DNA回收试剂盒回收目的片段并测定其浓度。按2∶1的摩尔比将扩增得到的短片段和长片段混合(总体积3μL)，随后添加3μL 2X Gibson装配预混试剂(2X Gibson Assembly Master Mix，购自NEB，包含T5exonuclease，Phusion DNA polymerase，Taq DNA ligase)，并在50℃反应1小时。
用装配后的产物(6μL)转化40μL以氯化钙法制备的感受态大肠杆菌ER2566(购自新英格兰生物实验室公司)。将经转化的大肠杆菌涂布于含卡那霉素的固体LB培养基，并在37℃静置培养10-12小时，直至单菌落清晰可辨。挑取单菌落至含有4mL液体LB培养基(含卡那霉素)的试管中，并在37℃220转/分钟下振荡培养10小时。随后，取1mL菌液于-70℃保存。从大肠杆菌中提取质粒，并利用T7引物对质粒中插入的目的片段的核苷酸序列进行测序。测序结果显示，所构建的各个质粒(表达载体)中插入的目的片段的核苷酸序列分别为SEQ ID NO：13、14、15、16，其编码的氨基酸序列 为SEQ ID NO：6、7、8、9(所对应的蛋白分别命名为H11N4-6T2，H11N4-6T3，H11N4-6T4，和H11N4-6T5)。
突变蛋白H11N4-6T2与HPV11N4的区别在于：位于野生型HPV11L1蛋白第119-140位的氨基酸残基被替换为野生型HPV6L1蛋白第119-139位的氨基酸残基。突变蛋白H11N4-6T3与HPV11N4的区别在于：位于野生型HPV11L1蛋白第170-179位的氨基酸残基被替换为野生型HPV6L1蛋白第169-178位的氨基酸残基。突变蛋白H11N4-6T4与HPV11N4的区别在于：位于野生型HPV11L1蛋白第257-288位的氨基酸残基被替换为野生型HPV6L1蛋白第256-287位的氨基酸残基。突变蛋白H11N4-6T5与HPV11N4的区别在于：位于野生型HPV11L1蛋白第346-351位的氨基酸残基被替换为野生型HPV6L1蛋白第345-350位的氨基酸残基。
表2.用于构建表达载体的PCR反应的模板和引物
模板 上游引物 下游引物 产物
11L1N4 H11N4-6T1-F H11N4-6T1-R H11N4-6T1
6L1N5 G-H11N4-6T2-F G-H11N4-6T2-R H11N4-6T2-短片段
11L1N4 G-V-H11N4-6T2-F G-V-H11N4-6T2-R H11N4-6T2-长片段
6L1N5 G-H11N4-6T3-F G-H11N4-6T3-R H11N4-6T3-短片段
11L1N4 G-V-H11N4-6T3-F G-V-H11N4-6T3-R H11N4-6T3-长片段
6L1N5 G-H11N4-6T4-F G-H11N4-6T4-R H11N4-6T4-短片段
11L1N4 G-V-H11N4-6T4-F G-V-H11N4-6T4-R H11N4-6T4-长片段
6L1N5 G-H11N4-6T5-F G-H11N4-6T5-R H11N4-6T5-短片段
11L1N4 G-V-H11N4-6T5-F G-V-H11N4-6T5-R H11N4-6T5-长片段
表3：所使用的引物的具体序列(SEQ ID NO：17-34)
Figure PCTCN2016108349-appb-000027
Figure PCTCN2016108349-appb-000028
突变蛋白的大量表达
从-70℃冰箱中取出携带重组质粒pT0-T7-H11N4-6T1、pT0-T7-H11N4-6T2、pT0-T7-H11N4-6T3、pT0-T7-H11N4-6T4、pT0-T7-H11N4-6T5的大肠杆菌菌液，分别接种入100ml含卡那霉素的LB液体培养基中，在200rpm，37℃下培养大约8小时；然后分别转接入500ml含卡那霉素的LB培养基中(接入1ml菌液)，并继续进行培养。当细菌浓度达到OD600为0.6左右时，将培养温度降至25℃，并向各培养瓶中加入500μL IPTG，继续培养8小时。培养结束后，离心收集菌体。获得表达了H11N4-6T1、H11N4-6T2、H11N4-6T3、H11N4-6T4和H11N4-6T5蛋白的菌体。
表达突变蛋白的菌体破碎
按1g菌体对应10mL裂解液(20mM Tris缓冲液，pH7.2，300mM NaCl)的比例重悬上述得到的菌体。用超声波仪破碎菌体30min。以13500rpm(30000g)离心含有经破碎的菌体的裂解液15min，留取上清(即，菌体破碎上清)。
突变蛋白的色谱纯化
仪器系统：GE Healthcare公司(原Amershan Pharmacia公司)生产的AKTA explorer 100型制备型液相色谱系统。
层析介质：SP Sepharose 4Fast Flow(GE Healthcare公司)、CHT-II(购自Bio-RAD)和Butyl Sepharose 4Fast Flow(GE Healthcare公司)。
缓冲液：20mM磷酸盐缓冲液，pH8.0，20mM DTT；以及，20mM磷酸盐缓冲液，pH8.0，20mM DTT，2M NaCl。
样品：如上获得的含有H11N4-6T1、H11N4-6T2、H11N4-6T3、H11N4-6T4和H11N4-6T5的菌体破碎上清。
洗脱程序为：
(1)用SP Sepharose 4Fast Flow对菌体破碎上清进行阳离子交换纯化：将样品上柱，然后用含有400mM NaCl的缓冲液洗脱杂蛋白，然后用含有800mM NaCl的缓冲液洗脱目的蛋白，并收集由含有800mM NaCl的缓冲液洗脱的级分；
(2)用CHTII(羟基磷灰石色谱)对前一步获得的洗脱级分进行色谱纯化：对前一步骤获得的洗脱级分进行稀释，以使得NaCl的浓度降至0.5M；将样品上柱，然后用含有500mM NaCl的缓冲液洗脱杂蛋白，然后用含有1000mM NaCl的缓冲液洗脱目的蛋白，并收集由含有1000mM NaCl的缓冲液洗脱的级分；
(3)用HIC(疏水相互作用色谱)对前一步骤获得的洗脱级分进行色谱纯化：将样品上柱，然后用含有1000mM NaCl的缓冲液洗脱杂蛋白，然后用含有200mM NaCl的缓冲液洗脱目的蛋白，并收集由含有200mM NaCl的缓冲液洗脱的级分。
取步骤(3)获得的洗脱级分150μL，加入30μL 6X Loading Buffer中，混匀，并于80℃水浴中温育10min。然后取10μl样品于10％SDS-聚丙烯酰胺凝胶中以120V电压电泳120min；然后以考马斯亮兰染色显示电泳条带。电泳结果示于图1中。结果显示，经过上述纯化步骤后，H11N4-6T1、H11N4-6T2、H11N4-6T3、H11N4-6T4和H11N4-6T5蛋白的纯度大于95％。
通过类似的方法，使用大肠杆菌和pT0-T7-HPV11N4C质粒制备和纯化了HPV11N4蛋白；并且，使用大肠杆菌和pT0-T7-HPV6N5C质粒制备和纯化了HPV6N5蛋白。
实施例2：HPV病毒样颗粒的组装与颗粒形态学检测
HPV病毒样颗粒的组装
取一定体积(约2ml)的蛋白H11N4-6T1、H11N4-6T2、H11N4-6T3、H11N4-6T4和H11N4-6T5，分别依次透析至(1)2L储存缓冲液(20mM磷酸钠缓冲液pH 6.5，0.5M NaCl)；(2)2L复性缓冲液(50mM磷酸钠缓冲液pH 6.0，2mM CaCl2，2mM MgCl2，0.5M NaCl)；和(3)20mM磷酸钠缓冲液pH 7.0，0.5M NaCl中。在三种缓冲液中各 自进行透析12h。
通过类似的方法，将HPV11N4和HPV6N5蛋白分别组装为HPV11N4VLP和HPV6N5VLP。
分子筛层析分析
用美国安捷伦公司的1120Compact LC高效液相色谱系统对经透析的样品进行分子筛层析分析，其中，所使用的分析柱为TSK Gel PW5000xl 7.8x300mm。分析结果如图2A-2F所示。结果显示，包含蛋白H11N4-6T1、H11N4-6T2、H11N4-6T3、H11N4-6T4和H11N4-6T5的样品最先出现的蛋白峰均在12min左右，与HPV11N4VLP相当。这表明，如上制备的蛋白均可组装成VLP。
沉降速率分析
沉降速率分析所使用的仪器为Beckman XL-A分析型超速离心机，其配有光学检测系统及An-50Ti和An-60Ti转头。采用沉降速率法分析HPV11N4VLP、H11N4-6T1VLP、H11N4-6T2VLP、H11N4-6T3VLP、H11N4-6T4VLP和H11N4-6T5VLP的沉降系数。结果如图3A-3F所示。结果显示，H11N4-6T1VLP、H11N4-6T2VLP、H11N4-6T3VLP、H11N4-6T4VLP和H11N4-6T5VLP的沉降系数分别为140S、138S、111S、139S和139S。这表明，如上制备的5种突变的HPV11L1蛋白各自能够组装成大小、形态与野生型VLP(HPV11N4VLP，136.3S)相似的病毒样颗粒。
病毒样颗粒的形态学检测
取100μL含有VLP的样品进行透射电镜观察。所使用的仪器为日本电子公司生产的100kV透射电镜，放大倍数为100,000倍。简言之，取13.5μL样品，用2％磷钨酸pH7.0进行负染，并固定于喷炭的铜网上，然后进行透射电镜观察。观察结果如图4A-4F所示。结果显示，H11N4-6T1、H11N4-6T2、H11N4-6T3、H11N4-6T4和H11N4-6T5均可组装成病毒样颗粒。此外，结果还显示，这些突变蛋白所组装形成的颗粒的半径均在25nm左右，大小均一。这表明，这些突变蛋白与野生型HPV11的L1蛋白(HPV11N4VLP)类似，能够形成大小均一的VLP。
实施例3：病毒样颗粒的热稳定性的评价
使用购自美国GE公司(原MicroCal公司)的差温量热仪VP Capillary DSC来评价HPV11N4、H11N4-6T1、H11N4-6T2、H11N4-6T3、H11N4-6T4和H11N4-6T5所形成的VLP的热稳定性，其中，使用所述蛋白的储存缓冲液作为对照，并且以1.5℃/min的升温速率在10℃-90℃区间对各蛋白进行扫描。检测结果如图5A-5F所示。结果显示，各个蛋白所形成的VLP均具有极高的热稳定性。
实施例4：H11N4-6T3VLP和H11N4-6T5VLP的三维结构的重建
根据之前报道的方法(Wolf M，Garcea RL，Grigorieff N.et al.Proc Natl Acad Sci U S A.(2010)，107(14)：6298-303)，使用冷冻电镜来重建H11N4-6T3VLP和H11N4-6T5VLP的三维结构。简而言之，使用冷冻电镜来观察H11N4-6T3VLP和H11N4-6T5VLP，随后在获得的H11N4-6T3VLP和H11N4-6T5VLP的冷冻电镜图像中(图6A和6C)，分别选取300和360个大小均一、直径超过50nm的颗粒，用于进行计算机重叠和结构重建，从而获取H11N4-6T3VLP和H11N4-6T5VLP的三维结构。所获得的三维结构如图6B和6D所示(分辨率分别为
Figure PCTCN2016108349-appb-000029
和
Figure PCTCN2016108349-appb-000030
)。结果显示，H11N4-6T3VLP和H11N4-6T5VLP是由72个壳粒(形态亚单位，五聚体)形成的T＝7的二十面体结构(h＝1，k＝2)。与一般的符合准等价原理的二十面体病毒衣壳不同，H11N4-6T3VLP和H11N4-6T5VLP结构中的所有亚单位均为五聚体，而不存在六聚体。并且，所述VLP的最外围直径为约60nm。这与之前报道的天然HPV病毒颗粒及通过真核表达系统(例如，痘病毒表达系统)制备的HPV VLP的三维结构(Baker TS，Newcomb WW，Olson NH.et al.Biophys J.(1991)，60(6)：1445-1456；Hagensee ME，Olson NH，Baker TS，et al.J Virol.(1994)，68(7)：4503-4505；Buck CB，Cheng N，Thompson CD.et al.J Virol.(2008)，82(11)：5190-7)类似。
实施例5：病毒样颗粒在动物体内的免疫保护性的评价
使用小鼠来评价由H11N4-6T1、H11N4-6T2、H11N4-6T3、H11N4-6T4和H11N4-6T5形成的VLP的免疫保护性。用于免疫接种的动物为，5-6周龄BalB/c普通级小鼠(购自上海斯莱康实验动物有限公司)。
将如上制备的HPV11N4VLP、HPV6N5VLP、H11N4-6T1VLP、H11N4-6T2VLP、 H11N4-6T3VLP、H11N4-6T4VLP、H11N4-6T5VLP和混合的HPV11/HPV6VLP(即，HPV11N4VLP和HPV6N5VLP的混合物)分别吸附于铝佐剂上。按不同的免疫原将小鼠分为8组，每组包含4只小鼠。免疫程序为：在0周时进行初次免疫；在第2和4周时各进行加强免疫一次。免疫方式为皮下注射，所使用的免疫原与剂量如表4所示。在初次免疫后的第8周，抽取眼球静脉血，并分离血清，随后检测血清中的中和抗体的滴度。检测结果如图7所示。结果显示，H11N4-6T3VLP和H11N4-6T5VLP各自可在小鼠体内诱导高滴度的针对HPV11和HPV6的中和抗体；并且其针对HPV11的保护效果与单独的HPV11N4VLP、混合的HPV11/HPV6VLP相当，且显著高于单独的HPV6N5VLP；并且其针对HPV6的保护效果与单独的HPV6N5VLP、混合的HPV11/HPV6VLP相当，且显著高于单独的HPV11N4VLP。H11N4-6T2VLP也可在小鼠体内诱导高滴度的针对HPV11和HPV6的中和抗体，但其诱导抗HPV6中和抗体的能力弱于H11N4-6T3VLP和H11N4-6T5VLP。这些结果表明，H11N4-6T2VLP、H11N4-6T3VLP和H11N4-6T5VLP可用作预防HPV11感染和HPV6感染的有效疫苗，可用于代替含有HPV11VLP和HPV6VLP的混合疫苗。
表4.免疫方案
Figure PCTCN2016108349-appb-000031
实施例6：用VLP免疫后小鼠血清中的中和抗体滴度的评价
在本实验中，免疫方案如表5所示。将所有小鼠(6周龄BalB/c雌性小鼠)分为 3个组：铝佐剂组1(免疫剂量为10μg，使用铝佐剂)，铝佐剂组2(免疫剂量为1μg，使用铝佐剂)，和铝佐剂组3(免疫剂量为0.1μg，使用铝佐剂)。各个组又细分为5个亚组，对照亚组1-3分别用单独的HPV11N4VLP、单独的HPV6N5VLP和混合的HPV11/HPV6VLP(即，HPV11N4VLP和HPV6N5VLP的混合物，其中每种VLP均以指定的免疫剂量施用)进行免疫，实验亚组1-2分别用H11N4-6T3VLP和H11N4-6T5VLP进行免疫。
采用腹腔注射方式免疫6只小鼠/亚组，免疫剂量分别为10μg、1μg、0.1μg，注射体积为1ml。所有小鼠均在第0周进行初次免疫，然后在第2和4周各自进行加强免疫一次。在第8周对小鼠进行眼眶采血，并分析血清中的抗HPV6和HPV11抗体的滴度。分析结果如图8A-8C所示。结果显示，H11N4-6T3VLP和H11N4-6T5VLP各自能诱导小鼠产生高滴度的针对HPV11的中和抗体，其保护效果与同剂量的单独的HPV11N4VLP、混合的HPV11/HPV6VLP相当，且显著优于同剂量的单独的HPV6N5VLP；并其能诱导小鼠产生高滴度的针对HPV6的中和抗体，其保护效果与同剂量的单独的HPV6N5VLP、混合的HPV11/HPV6VLP相当，且显著优于同剂量的单独的HPV11N4VLP。这表明，H11N4-6T3VLP和H11N4-6T5VLP各自对HPV11和HPV6具有良好的交叉免疫原性和交叉保护性。
表5.免疫方案
Figure PCTCN2016108349-appb-000032
Figure PCTCN2016108349-appb-000033
实施例7：VLP诱导血清转换的ED50的评价
采用铝佐剂、单次腹腔注射方式对6周龄的BalB/c雌鼠(8只)进行免疫，其中，实验组使用H11N4-6T3VLP或H11N4-6T5VLP(免疫剂量为0.300μg、0.100μg、0.033μg或0.011μg)；对照组使用单独的HPV6N5VLP或单独的HPV11N4VLP(免疫剂量为0.300μg、0.100μg、0.033μg或0.011μg)，或者混合的HPV11/HPV6VLP(即，HPV6N5VLP和HPV11N4VLP的混合物，其中每种VLP的免疫剂量各为0.300μg、0.100μg、0.033μg、0.011μg或0.004μg)；免疫体积为1mL。另外，还将用于稀释疫苗的稀释液用作空白对照。每组免疫8只小鼠，并且于免疫后第五周采集血清。随后，通过中和实验检测血清中的中和抗体滴度，并根据Reed-Muench法(Reed LJ MH.A simple method of estimating fifty percent endpoints.Am J Hyg.1938；27：493-7)计算各个样品诱导血清转换(即，诱导小鼠产生抗体)的ED50。实验结果如表6.1-6.5所示。
表6.1：HPV6N5VLP诱导小鼠产生抗HPV6和抗HPV11抗体(血清转换)的ED50
Figure PCTCN2016108349-appb-000034
Figure PCTCN2016108349-appb-000035
表6.2：H11N4-6T3VLP诱导小鼠产生抗HPV6和抗HPV11抗体(血清转换)的ED50
Figure PCTCN2016108349-appb-000036
表6.3：H11N4-6T5VLP诱导小鼠产生抗HPV6和抗HPV11抗体(血清转换)的ED50
Figure PCTCN2016108349-appb-000037
表6.4：HPV11N4VLP诱导小鼠产生抗HPV6和抗HPV11抗体(血清转换)的ED50
Figure PCTCN2016108349-appb-000038
表6.5：混合的HPV11/HPV6VLP诱导小鼠产生抗HPV6和抗HPV11抗体(血清转换)的ED50
Figure PCTCN2016108349-appb-000039
结果显示，H11N4-6T3VLP和H11N4-6T5VLP诱导小鼠产生抗HPV6抗体的ED50与单独的HPV6N5VLP和混合的HPV11/HPV6VLP相当，且显著优于单独的HPV11N4VLP；并且，H11N4-6T3VLP和H11N4-6T5VLP诱导小鼠产生抗HPV11抗体的ED50与单独的HPV11N4VLP和混合的HPV11/HPV6VLP相当，且显著优于单独的HPV6N5VLP。这进一 步表明，H11N4-6T3VLP和H11N4-6T5VLP对HPV6和HPV11具有良好的交叉免疫原性和交叉保护性。
实施例8：H11N4-6T3VLP和H11N4-6T5VLP在食蟹猴体内的免疫保护性的评价
将18只体重相近的食蟹猴随机分成3组(每组6只猴子)，其中，第一组猴子接种5μg的H11N4-6T3VLP；第二组猴子接种5μg的H11N4-6T5VLP；第三组猴子接种10μg混合的HPV11/HPV6VLP(5μg HPV6N5VLP+5μg HPV11N4VLP)。所使用的佐剂均为铝佐剂，注射体积为1ml，并且采用肌肉注射方式进行免疫。免疫方案如表7所示。
免疫两个月后，采集静脉血，并通过中和实验检测血清中的中和抗体滴度。实验结果如图9所示。结果显示，H11N4-6T3VLP和H11N4-6T5VLP各自可在食蟹猴体内诱导针对HPV11和HPV6的中和抗体；并且所诱发的中和抗体的滴度与混合的HPV11/HPV6VLP诱发的中和抗体的滴度相当。这些结果表明，H11N4-6T3VLP和H11N4-6T5VLP各自在食蟹猴中具有良好的免疫原性，且能诱导针对HPV6和HPV11的交叉保护作用，其针对HPV11和HPV6的保护效果与混合的HPV11/HPV6VLP相当。因此，H11N4-6T3VLP和H11N4-6T5VLP可用于预防HPV6和HPV11的感染。
表7.食蟹猴的免疫方案
免疫原 佐剂 免疫剂量 数量 免疫程序
混合的HPV11/HPV6VLP 铝佐剂 10μg(每种VLP各5μg) 6 单次注射
H11N4-6T3VLP 铝佐剂 5μg 6 单次注射
H11N4-6T5VLP 铝佐剂 5μg 6 单次注射
尽管本发明的具体实施方式已经得到详细的描述，本领域技术人员将会理解，根据已经公开的所有教导，可以对那些细节进行各种修改和替换，这些改变均在本发明的保护范围之内。本发明的全部范围由所附权利要求及其任何等同物给出。

Claims (11)

  1. 一种突变的HPV11 L1蛋白或其变体，其中，所述突变的HPV11 L1蛋白与野生型HPV11 L1蛋白相比，具有下述突变：
    (1)N端截短了3-6个氨基酸，例如3个、4个、5个或6个氨基酸；和
    (2)(a)位于野生型HPV11 L1蛋白第170-179位的氨基酸残基被替换为第二型别的野生型HPV L1蛋白的相应位置的氨基酸残基；或
    (b)位于野生型HPV11 L1蛋白第346-351位的氨基酸残基被替换为第二型别的野生型HPV L1蛋白的相应位置的氨基酸残基；或
    (c)位于野生型HPV11 L1蛋白第119-140位的氨基酸残基被替换为第二型别的野生型HPV L1蛋白的相应位置的氨基酸残基；
    并且，所述变体与所述突变的HPV11 L1蛋白相异仅在于一个或几个(例如，1个、2个、3个、4个、5个、6个、7个、8个或9个)氨基酸的置换(优选保守置换)、添加或缺失，且保留了所述突变的HPV11 L1蛋白的功能，即，能够诱导针对至少两个型别的HPV(例如，HPV11和HPV6)的中和抗体；
    优选地，所述突变的HPV11 L1蛋白与野生型HPV11 L1蛋白相比，N端截短了3个、4个、5个或6个氨基酸；
    优选地，所述突变的HPV11 L1蛋白与野生型HPV11 L1蛋白相比，N端截短了4个氨基酸；
    优选地，所述第二型别的野生型HPV为HPV6；
    优选地，(2)(a)中所述的相应位置的氨基酸残基为野生型HPV6 L1蛋白第169-178位的氨基酸残基；
    优选地，(2)(b)中所述的相应位置的氨基酸残基为野生型HPV6 L1蛋白第345-350位的氨基酸残基；
    优选地，(2)(c)中所述的相应位置的氨基酸残基为野生型HPV6 L1蛋白第119-139位的氨基酸残基；
    优选地，所述野生型HPV11 L1蛋白具有如SEQ ID NO：1所示的氨基酸序列；
    优选地，所述野生型HPV6 L1蛋白具有如SEQ ID NO：2所示的氨基酸序列；
    优选地，所述突变的HPV11 L1蛋白具有选自下列的氨基酸序列：SEQ ID NO：6、 7和9。
  2. 一种分离的核酸，其编码权利要求1所述的突变的HPV11 L1蛋白或其变体。
  3. 包含权利要求2所述的分离的核酸的载体。
  4. 包含权利要求2所述的分离的核酸和/或权利要求3所述的载体的宿主细胞。
  5. 一种HPV病毒样颗粒，其含有权利要求1所述的突变的HPV11 L1蛋白或其变体，或者由权利要求1所述的突变的HPV11 L1蛋白或其变体组成。
  6. 一种组合物，其包含权利要求1所述的突变的HPV11 L1蛋白或其变体，或权利要求2的分离的核酸，或权利要求3的载体，或权利要求4的宿主细胞，或权利要求5的HPV病毒样颗粒。
  7. 一种药物组合物或疫苗，其包含权利要求5的HPV病毒样颗粒，任选地还包含药学可接受的载体和/或赋形剂，
    优选地，所述HPV病毒样颗粒以预防HPV感染或由HPV感染导致的疾病的有效量存在；
    优选地，所述HPV感染是一个或多个型别的HPV感染(例如，HPV11感染和/或HPV6感染)；
    优选地，所述由HPV感染所导致的疾病选自宫颈癌和尖锐湿疣。
  8. 制备权利要求1所述的突变的HPV11 L1蛋白或其变体的方法，其包括，在宿主细胞中表达所述突变的HPV11 L1蛋白或其变体，然后从所述宿主细胞的培养物中回收所述突变的HPV11 L1蛋白或其变体；
    优选地，所述宿主细胞为大肠杆菌；
    优选地，所述方法包括步骤：在大肠杆菌中表达所述突变的HPV11 L1蛋白或其变体，然后从所述大肠杆菌的裂解上清中纯化得到所述突变的HPV11 L1蛋白或其变体； 优选地，通过色谱法(例如，阳离子交换色谱，羟基磷灰石色谱和/或疏水相互作用色谱)，从所述大肠杆菌的裂解上清中回收所述突变的HPV11 L1蛋白或其变体。
  9. 一种制备疫苗的方法，其包括将权利要求5的HPV病毒样颗粒与药学可接受的载体和/或赋形剂混合。
  10. 一种预防HPV感染或由HPV感染所导致的疾病的方法，其包括将预防有效量的权利要求5的HPV病毒样颗粒或权利要求7的药物组合物或疫苗施用给受试者，
    优选地，所述HPV感染是一个或多个型别的HPV感染(例如，HPV11感染和/或HPV6感染)；
    优选地，所述由HPV感染所导致的疾病选自宫颈癌和尖锐湿疣。
  11. 权利要求1所述的突变的HPV11 L1蛋白或其变体或权利要求5的HPV病毒样颗粒在制备药物组合物或疫苗中的用途，所述药物组合物或疫苗用于预防HPV感染或由HPV感染所导致的疾病，
    优选地，所述HPV感染是一个或多个型别的HPV感染(例如，HPV11感染和/或HPV6感染)；
    优选地，所述由HPV感染所导致的疾病选自宫颈癌和尖锐湿疣。
PCT/CN2016/108349 2015-12-04 2016-12-02 一种人乳头瘤病毒11型l1蛋白的突变体 WO2017092711A1 (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2018548264A JP6920694B2 (ja) 2015-12-04 2016-12-02 ヒトパピローマウイルスタイプ１１のｌ１タンパク質の突然変異
US15/781,328 US10513541B2 (en) 2015-12-04 2016-12-02 Mutant of L1 protein of human papillomavirus type 11
BR112018011331-0A BR112018011331A2 (pt) 2015-12-04 2016-12-02 mutante de proteìna l1 de papillomavirus humano tipo 11
KR1020187018923A KR20180084139A (ko) 2015-12-04 2016-12-02 11형 인유두종 바이러스 엘1 단백질의 돌연변이체
EP16870021.9A EP3385274B1 (en) 2015-12-04 2016-12-02 Mutant of human papillomavirus type 11 l1 protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510887801.9 2015-12-04
CN201510887801 2015-12-04

Publications (1)

Publication Number Publication Date
WO2017092711A1 true WO2017092711A1 (zh) 2017-06-08

Family

ID=58796324

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/108349 WO2017092711A1 (zh) 2015-12-04 2016-12-02 一种人乳头瘤病毒11型l1蛋白的突变体

Country Status (7)

Country Link
US (1) US10513541B2 (zh)
EP (1) EP3385274B1 (zh)
JP (1) JP6920694B2 (zh)
KR (1) KR20180084139A (zh)
CN (1) CN106831958B (zh)
BR (1) BR112018011331A2 (zh)
WO (1) WO2017092711A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021013069A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒11型l1蛋白
CN114127099B (zh) * 2019-07-19 2024-04-19 神州细胞工程有限公司 嵌合的人乳头瘤病毒6型l1蛋白
CN115803051A (zh) 2020-05-14 2023-03-14 艾诺奥医药品有限公司 用于复发性呼吸道乳头状瘤病的疫苗及其使用方法
CN114539363B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种c端改造的人乳头瘤病毒11型l1蛋白及其用途
KR20230126566A (ko) 2022-02-23 2023-08-30 충남대학교산학협력단 핵수송 신호 펩타이드가 접합된 핵산 전달용 2세대 폴리아미도아민 덴드리머 고분자 유도체
CN116041445B (zh) * 2023-01-06 2023-09-05 北京康乐卫士生物技术股份有限公司 一种人乳头瘤病毒51型l1蛋白突变体及减少重组蛋白降解的方法及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1185810A (zh) * 1995-03-30 1998-06-24 麦克公司 编码人乳头瘤病毒11型l1蛋白的合成的hpv6/11杂交l1dna
US5795754A (en) * 1995-07-19 1998-08-18 Merck & Co., Inc. Synthetic HPV11 virus-like particles
WO2000035478A1 (en) * 1998-12-11 2000-06-22 The University Of Queensland Treatment of papillomavirus infections
US6689366B1 (en) * 1998-12-17 2004-02-10 Merck & Co., Inc. Synthetic virus like particles with heterologous epitopes
CN101343314A (zh) * 2007-05-29 2009-01-14 厦门大学 截短的人乳头瘤病毒11型l1蛋白
CN102747047A (zh) * 2012-02-28 2012-10-24 厦门大学 人乳头瘤病毒型别杂合病毒样颗粒及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5738853A (en) * 1995-11-15 1998-04-14 Merck & Co., Inc. Synthetic HPV11 virus-like particles
ES2213185T3 (es) * 1995-11-15 2004-08-16 MERCK & CO., INC. Particulas de tipo virus hpv11 sinteticas.
BRPI0810951B8 (pt) * 2007-05-29 2021-05-25 Beijing Wantai Biological Pharmacy Entpr Co Ltd proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv
CN101518647A (zh) * 2008-02-29 2009-09-02 江阴艾托金生物技术有限公司 人乳头瘤病毒预防性疫苗、构建方法及应用
DK2324113T3 (en) * 2008-08-08 2018-04-16 Takeda Vaccines Inc VIRUS-LIKE PARTICLES INCLUDING COMPOSITE CAPSID AMINO ACID SEQUENCES FOR INCREASED CRYSTAL REACTIVITY
CN102229660B (zh) * 2011-05-25 2015-04-22 厦门大学 截短的人乳头瘤病毒33型l1蛋白
CN104211782B (zh) * 2013-06-04 2017-11-17 厦门大学 截短的人乳头瘤病毒45型l1蛋白

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1185810A (zh) * 1995-03-30 1998-06-24 麦克公司 编码人乳头瘤病毒11型l1蛋白的合成的hpv6/11杂交l1dna
US5795754A (en) * 1995-07-19 1998-08-18 Merck & Co., Inc. Synthetic HPV11 virus-like particles
WO2000035478A1 (en) * 1998-12-11 2000-06-22 The University Of Queensland Treatment of papillomavirus infections
US6689366B1 (en) * 1998-12-17 2004-02-10 Merck & Co., Inc. Synthetic virus like particles with heterologous epitopes
CN101343314A (zh) * 2007-05-29 2009-01-14 厦门大学 截短的人乳头瘤病毒11型l1蛋白
CN102747047A (zh) * 2012-02-28 2012-10-24 厦门大学 人乳头瘤病毒型别杂合病毒样颗粒及其制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LUDMERER, S.W. ET AL.: "HPV 11 Mutant Virus-Like Particles Elicit Immune Responses That Neutralize Virus and Delineate a Novel Neutralizing Domain", VIROLOGY, vol. 266, 31 December 2000 (2000-12-31), pages 237 - 245, XP002216860 *
MCCLEMENTS, W.L. ET AL.: "A Novel Human Papillomavirus Type 6 Neutralizing Domain Comprising Two Discrete Regions of the Major Capsid Protein LI", VIROLOGY, vol. 289, 31 December 2001 (2001-12-31), pages 262 - 268, XP055387274 *
See also references of EP3385274A4 *

Also Published As

Publication number Publication date
US20190062379A1 (en) 2019-02-28
EP3385274A4 (en) 2019-08-14
EP3385274B1 (en) 2021-09-22
JP6920694B2 (ja) 2021-08-18
CN106831958B (zh) 2020-12-29
KR20180084139A (ko) 2018-07-24
EP3385274A1 (en) 2018-10-10
CN106831958A (zh) 2017-06-13
JP2019502404A (ja) 2019-01-31
US10513541B2 (en) 2019-12-24
BR112018011331A2 (pt) 2019-04-30

Similar Documents

Publication Publication Date Title
US10940194B2 (en) Mutant of L1 protein of human papillomavirus type 58
WO2017092711A1 (zh) 一种人乳头瘤病毒11型l1蛋白的突变体
US11427618B2 (en) Mutant of L1 protein of human papillomavirus type 39
JP7290258B2 (ja) ヒトパピローマウイルス５１型のｌ１タンパク質の変異型
US11213580B2 (en) Mutant of L1 protein of human papillomavirus type 16
JP7265563B2 (ja) ヒトパピローマウイルス１８型のｌ１タンパク質の変異体
US11464846B2 (en) Mutant of L1 protein of human papillomavirus type 66

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16870021

Country of ref document: EP

Kind code of ref document: A1

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2018548264

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20187018923

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020187018923

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2016870021

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016870021

Country of ref document: EP

Effective date: 20180704

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018011331

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112018011331

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180604